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ABSTRACT

THE PROGNOSTIC POTENTIAL OF THE EPIDERMAL GROWTH FACTOR
RECEPTOR AND NUCLEAR FACTOR KAPPA B PATHWAYS AND ASSOCIATED
THERAPEUTIC STRATEGIES IN PATIENTS WITH SQUAMOUS CELL
CARCINOMA OF THE HEAD AND NECK
By Pamela Susan Wirth, Ph.D.
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2010
Major Director: Teresa S. Nadder, Ph.D.
Chairman and Associate Professor, Department of Clinical Laboratory Sciences

Little is known about the signaling pathways that contribute to treatment response in
advanced stage head and neck tumors. Increased expression of epidermal growth factor
receptor (EGFR) and downstream pathways such as nuclear factor kappa B (NFκB) are
implicated in aggressive tumor phenotypes and limited response to therapy. This study
explored the rationale for combining the proteasome inhibitor bortezomib with the EGFR
inhibitor gefitinib in a subset of head and neck squamous cell carcinomas with high
EGFR gene amplification. Drug responses of gefitinib and bortezomib as single agents
and in combination within head and neck squamous cell carcinoma cell lines were
analyzed using MTS assays. The effects of gefitinib on the activation of EGFR and
itsthree major downstream pathways, Akt, STAT3 and MAPK were determined by

western blotting. The activation status of NFκB and the effects of bortezomib on the
canonical pathway were assessed by DNA binding assays. Resistance to lower doses of
gefitinib was associated with elevated EGFR and activated Akt expression. Gefitinib was
able to effectively inhibit activation of STAT3, Akt and MAPK in HNSCC to varying
degrees depending on EGFR expression status. Bortezomib treatment inhibited TNFα –
induced nuclear NFκB/RelA expression but demonstrated variability in levels of baseline
nuclear NFκB/RelA expression between sensitive and resistant cell lines. Bortezomib
effectively suppresses NFκB/RelA nuclear activation but demonstrates additional modes
of cellular toxicity beyond the NFκB pathway in sensitive cell lines. Further
understanding of tumor response to the targeted inhibitors gefitinib and bortezomib may
provide novel approaches in managing HNSCCs.

CHAPTER 1: INTRODUCTION

Background
Head and neck cancers comprise about five percent of all cancers in the United
States. These malignant tumors can arise in the lip and oral cavity, nasal cavity, pharynx,
larynx, thyroid, paranasal sinuses, salivary glands and cervical lymph nodes of the neck.
The majority of head and neck cancers involve epithelial tissues and are classified as
squamous cell carcinomas. Head and neck squamous cell carcinomas (HNSCCs)
predominantly affect males over 40 years of age with major risk factors including
tobacco and alcohol use (Sanderson & Ironside, 2002). Human papillomavirus is a
significant risk factor for oropharynx carcinomas and has been found to be associated
with approximately 20 to 25% of head and neck tumors (Chung & Gillison, 2009).
Many different treatments and therapies are used in the management of head and
neck cancer. The type of treatment and therapy depends largely on the location of the
tumor and the extent of metastasis at the time of diagnosis (Choong & Vokes, 2008). The
lack of survival benefit from current therapies for advanced stage patients has prompted
the search for markers that may provide therapeutic targets such as nuclear factor kappa
B (NFκB) and epidermal growth factor receptor (EGFR) pathways. NFκB and EGFR are
key players in the regulation of cell proliferation and survival and are known to be
deregulated in head and neck tumors (Chung, Parker, Ely, Carter, Yi, Murphy, et al.,
1
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2006). There is an urgent need to identify prognostic markers that may reliably predict a
subset of patients responsive to these pathway-targeted therapies. Currently the
preclinical evidence necessary to demonstrate the efficacy of combination therapies is
lacking. The use of two agents, bortezomib, an NFκB pathway inhibitor, and gefitinib, an
anti-EGFR tyrosine kinase inhibitor, were examined for their efficiency as combination
agents in head and neck carcinomas.
Clinical Management of Head and Neck Cancer
Staging of the tumor remains the standard method of determining treatment modality and
prognostic outcome for the patient, although reliability and effectiveness are
questionable. Survival rates for head and neck cancer have not significantly improved
over the past 25 years as advanced-stage patients experience only a five year relative
survival rate at approximately 50% (Chin, Boyle, Porceddu, Theile, Parsons, & Coman,
2006). Treatment regimens involve surgical resection, radiotherapy and/or chemotherapy.
The choice of treatment is unique to each patient depending upon cancer staging, the
desire for organ preservation or previous response to treatment (Spencer, Ferguson, &
Wiesenfeld, 2002). When achievable, organ preservation is the preferred goal for many
patients. Issues reported with organ loss in head and neck patients involve difficulty with
swallowing, speech, eating and respiration. Chemotherapy in combination with radiation
without surgical intervention for the purpose of larynx preservation has shown success in
improving the quality of life in patients with site specific cancers such as the larynx and
hypopharynx. Chemoradiotherapy in conjunction with surgical resection has become the
standard method of care for the majority of locally advanced HNSCCs, not only for the
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benefit of potential organ preservation but also to improve treatment success over
radiation alone. Altered combinations of chemotherapy and radiotherapy may include:
induction chemotherapy (chemotherapy given before radiotherapy), adjuvant
chemotherapy (chemotherapy given after radiotherapy), and concurrent or concomitant
chemoradiotherapy (chemotherapy given at the same time as radiotherapy). Concurrent
chemoradiotherapy has proven the most successful nonsurgical option (Choong & Vokes,
2008).
Common chemotherapy agents include the taxanes, 5-fluorouracil (5-FU) and
platinum-derivatives. The taxanes are a group of drugs that target microtubules,
intracellular proteins that assist in cellular support and movement. Paclitaxel (Taxol) and
docetaxel (Taxotere) are commonly used anti-microtubule agents in the treatment of head
and neck cancer which act to prevent the disassembling of these cellular proteins.
Microtubules then accumulate in excess, preventing the cancer cells from growing and
dividing. Two of the most common platinum chemotherapeutic agents used in
combination therapy are cisplatin and 5-FU. These platinum agents bind and cross-link
DNA preventing cell division ultimately resulting in apoptosis of cancer cells. 5-FU
specifically blocks the synthesis of thymidine, a nucleotide required for DNA replication
(Bernier & Bentzen, 2006).
Radiation therapy is measured in gray (Gy), the unit measurement to indicate the
amount of dose applied to the patient. A standard radiation dose and schedule for head
and neck patients involves daily fractions of 1.8 to 2 Gy for five days over five to seven
weeks. Accelerated schedules may be employed with more frequent dosing during the
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five day treatment schedule or include additional days of treatment during the week.
Radiation can also be used to help sensitize tumors to chemotherapeutic agents and
improve local tumor control. Common side effects caused by radiation and/or
combination treatments specifically affecting the quality of life for many head and neck
patients are pain, increased inflammation, accumulation of mucous in airways and weight
loss. These place a particularly increased burden on older patients and/or those with
comorbidities (Lalami, de Castro, Bernard-Marty, & Awada, 2009).
Targeted agents are specifically being investigated as a means of reducing toxicity
and overcoming treatment resistance. Targeted agents are less likely to have toxic effects
on surrounding normal tissues or cells that do not express a specific receptor or molecule.
Recent clinical trials have investigated the impact of combining targeted therapies such as
EGFR inhibitors gefitinib with cisplatin or 5-FU, demonstrating improved survival rates
over single agent platinum-based chemotherapy regimens. These results indicate the
addition of EGFR inhibitors to chemotherapy in patients with metastatic HNSCC is
beneficial in terms of improved survival rates over the use of single agents. The addition
of targeted agents with standard chemotherapy resulted in an improvement in median
survival from 7.4 months to 10.1 months. Unfortunately, improving overall survival rates
among all tumor sites and stages continues to present a challenge (Choong & Vokes,
2008).
Approximately 70% of HNSCC patients presenting without metastasis receive
aggressive therapy due to the difficulty in determining patient response to treatment
(Yarbrough, Slebos, & Liebler, 2006). With radiation treatment alone, survival rates
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average a mere 12 months. Chemoradiotherapy can extend average overall survival rates
(67% versus 37% with radiation alone) in site specific tumors such as the nasopharynx
and oropharynx. Although overall survival rates remain unchanged in other sites such as
the larynx and hypopharynx, organ preservation is still often possible preserving the
voice and an intact airway (Marur & Forastiere, 2008).
Combination treatments with radiation and chemotherapy can be beneficial in
terms of organ preservation but present additional obstacles in terms of increased
toxicities. As much as one-third of patients are unable to maintain the full course regimen
due to severe side effects. Toxicities such as permanent dry mouth and difficulty
swallowing are comparable with both single agent and combination therapies. For those
patients able to withstand the concurrent chemoradiotherapy treatments, some studies
show significant improvement in overall survival and locoregional control rate when
compared to radiotherapy alone. A large phase III study demonstrated an overall survival
benefit (49% versus 24%) and 3-year locoregional control rate (35% versus 17%) with
chemoradiotherapy treatment over radiation alone; however, this benefit was primarily
confined to oropharynx tumors (Bernier & Schneider, 2007).
The EGFR Pathway in Head and Neck Cancers
EGFR exists on the cell surface and is activated by the binding of specific ligands,
including epidermal growth factor (EGF) and transforming growth factor alpha (TGFα).
The ErbB family consists of four family members, ErbB1, ErbB2, ErbB3 and ErbB4.
EGFR is also known as ErbB1 or HER1. ErbB2, ErbB3 and ErbB4 are also known as
HER2, HER3 and HER4, respectively. The ErbB receptor group belongs to a family of
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numerous growth signals including EGF and TGFα. Receptor tyrosine kinases are
transmembrane glycoproteins with a cysteine rich ligand-binding extracellular domain, a
transmembrane domain, and an intracellular tyrosine kinase domain with a tyrosine rich
C-terminal tail. Activation of the ligand-binding domain by the binding of an
extracellular ligand leads to homodimerization or heterodimerization among the members
of the ErbB family. Upon activation by its growth factor ligands, EGFR may form a
homodimer by binding with another ErbB1 receptor or form a heterodimer by binding
with other members of the family (Bianco, 2004). The joining of receptors induces the
activation of the tyrosine kinase domain of the EGFR, recruitment of a number of adaptor
proteins, followed by initiation of downstream signaling cascades (Arteaga, 2002).
Several investigators determined that HER2 does not appear to have relevance as
a prognostic marker in head and neck cancer as gene mutations are low to absent in head
and neck tumors (Ali, Gunduz, Gunduz, Tamamura, Beder, Katase, et al., 2009; Tse, Yu,
Chan, King, Chen, Wong, et al., 2009; Low, Ch’ng, Ng, Sullivan, Brasch, Davis, et al.,
2009). Eckberg et al studied 19 cases of metastatic HNSCCs by immunohistochemistry
(IHC) and did not find protein expression differences in either HER3 or HER4 between
tumor and matched normal tissues (Eckberg, Nestor, Engstrom, Nordgren, Webster,
Carlsson, et al., 2005). Wheeler et al demonstrated HNSCC cells show low baseline
HER3 and HER4 levels but upon acquired resistance to the extracellular EGFR inhibitor
cetuximab, demonstrate significant activation of HER2 and HER3 (Wheeler, Huang,
Kruser, Nechrebecki, Armstrong, Benavente, et al., 2008). Upregulation of the receptor
as a mechanism of acquired EGFR inhibitor resistance may result in increased
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heterodimerization with other ErbB family members, potentially activating downstream
signaling pathways (Arteaga, 2002).
EGFR expression is highly elevated in head and neck cancers; and upon EGFR
activation, sets off downstream signaling proteins to initiate cell proliferation and
survival, principally the mitogen activated protein kinase (MAPK), Akt and STAT
(Signal Transducers and Activators of Transcription) pathways. Tumors with a high risk
of poor clinical outcome cluster separately based on gene expression analysis from other
intermediate or low risk tumors with an expression profile reflective of EGFR activation
(Chung, Levy, &Yarbrough, 2005). Akt contributes to cell survival pathways by
inhibiting programmed cell death or apoptosis. Since it can block apoptosis, and thereby
promote cell survival, Akt has been implicated as a major factor in many types of cancer.
Akt’s normal functions are to regulate the cell cycle, survival and support metabolism by
binding and regulating many downstream factors such as NFκB (Marmor, Skaria, &
Yarden, 2004). Akt can activate NFκB through the alternative pathway by binding to
IKKα, an NFκB activator. IKKα is then able to phosphorylate the NFκB inhibitor IκB
that normally serves to sequester NFκB/RelB in an inactive state within the cytoplasm.
Once released from its inhibitor, NFκB is able to translocate to the nucleus activating
several proinflammatory and anti-apoptotic signals (Nakayama, Ikebe, Beppu, &
Shirasuna, 2001).
The three main signaling pathways induced by ligand stimulation of the EGFR
include Ras/MAPK, STAT and PI3K/Akt. EGFR exists on the cell surface and is
activated by binding of its specific ligands. Two structurally similar subunits of the
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EGFR called monomers join together or dimerize when bound to an activating ligand like
EGF or TGFα. EGFR dimerization initiates phosphorylation of the receptor and
stimulates its intracellular protein-tyrosine domain. This elicits downstream activation
and signaling of proteins, principally the MAPK, Akt, and STAT pathways involved in
DNA synthesis, cell proliferation, and cell migration (Figure 1).

Figure 1. The Three Main Signaling Pathways Induced by EGFR Stimulation Including
MAPK, STAT and PI3K/Akt.
Of the seven known ligands that bind to the EGFR, EGF and transforming growth
factor alpha (TGFα) are the most well-known. Other factors outside of ligands can cause
activation of the receptor, including radiation and chemotherapy. EGFR can be
phosphorylated and translocated to the nucleus upon irradiation and cellular stress as
shown in DNA precipitation assays and confocal microscopy (Dittman, Mayer,
Fehrenhacher, Schaller, Raju, Milas, et al., 2005). Mutations in the tyrosine kinase
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domain of EGFR can act as activating mutations in a ligand-independent manner, leading
to tumor-cell dependence on EGFR signaling (Sharma, Bell, Settleman, & Haber, 2007).
The phosphorylation of the growth factor receptor stimulates the downstream activation
of several proteins that influence cell division, migration and survival (Scaltriti &
Baselga, 2006).
The Ras/MAPK/ERK pathway plays a vital role in regulating cell responses
through EGFR. Multiple downstream effectors are phosphorylated, then translocated to
the nucleus, promoting tumor cell invasion, increased vessel growth and altered gene
expression. Upon activation of the EGFR, the Ras/Raf/MAPK pathway initiates
translocation of MAPK into the nucleus. Once in the nucleus, MAPK activates specific
transcription factors which regulate cell proliferation and growth. Akt is a central
mediator in a number of pathways as a promoter of cell survival and migration through
the inactivation of glycogen synthase kinase 3 (GSK-3). GSK-3 inactivation leads to
increased glycogen and protein synthesis. GSK-3 inactivation also prevents the
degradation of β-catenin, allowing it to build up in the cytoplasm with subsequent
translocation into the nucleus. β-catenin can function as an oncogene leading to increased
cell proliferation. Akt’s anti-apoptotic activities are also carried out through NFκB and
Bad, a member of the Bcl-2 family member that governs a cell’s overall homeostatic
balance between growth and death (Scaltriti & Baselga, 2006).
STAT, signal transducer and activator of transcription, is a family of proteins
involved in normal and oncogenic pathways. Of the seven members of the STAT family
of proteins, STAT3 and STAT5 are the most highly studied. They are activated by a wide
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range of hormones, cytokines and growth factors including EGF. Only STAT3 has been
shown to be critical for early development. Other growth-promoting functions of this
protein include wound healing, cell division and liver regeneration (Lim & Cao, 2006).
The overexpression of STAT3 is associated with several tumor types including leukemia,
prostate, breast and head and neck. Elevation in STAT3 expression is possible through
growth factor pathways like EGFR as well as inflammatory pathways in an
autostimulatory manner. Once activated, STAT proteins are able to initiate cellular
proliferation through gene transcription (Marmor et al., 2004). Blockage of the EGFR
and NFκB pathways decreases STAT3 activity in head and neck squamous carcinoma
cells (Squarize, Castilho, Sriuranpong, Pinto, & Gutkind, 2006).
Akt (also known as protein kinase B, PKB) is activated as a result of PI3-kinase
(PI3K) activity and through its downstream effectors, coordinates cell growth, invasion,
metastasis and cell survival. The first evidence pointing to a role of Akt in oncogenesis
was provided by early studies of the retrovirus AKT8 isolated from the AKR mouse.
AKR mice have a tendency to contract spontaneous T cell lymphomas as a result of low
tolerance to viruses. AKT8 was later shown to transform epithelial cells to a more
malignant phenotype. In 1981, the human homologue of the AKT8 retrovirus was
discovered. The nonviral, oncogenic counterpart was designated v-Akt (Staal, 1987).
There are three forms of Akt: Akt1, Akt 2, and Akt 3. Although all three forms are
similar in size and composition, Akt 1 and 2 play a more important role in pathological
signaling. Akt 3 is less relevant to the cancer phenotype as it has a more restricted
expression pattern in the brain and testes. Binding of growth factors such as EGF or
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TGFα to their receptors leads to stimulation of Akt, blocking the activation of a number
of targets including the pro-apoptotic protein BAD, GSK-3 (anti-apoptotic functions) as
well as activating cell growth proteins like mTOR (promotes hypertrophy), Raf (a
member of the MAPK pathway) and NFκB/p65 (Song, Ouyang, & Bao, 2005).
The activation of EGFR and its downstream signal transduction kinases is known
to modulate tumor development, progression and therapeutic resistance. The activation of
these intermediaries has been implicated in the upregulation of NFκB, which has been
described in many cancer cell types as a supporter of tumor invasion, metastasis and
proliferation (Bancroft, Chen, Yeh, Sunwoo, Yeh, Jackson et al., 2002).
Role of NFκB Pathway in HNSCCs
NFκB, a factor in the nucleus of B cells that binds to the enhancer of the kappa light chain
of immunoglobulin was first discovered in the lab of David Baltimore in 1986. It was
originally believed to be required only for B cell maturation and development but is now
known to be expressed ubiquitously (Sun & Andersson, 2002). A pro-inflammatory
transcription factor, NFκB is part of a large family of transcription factors that regulate
normal cellular processes such as immune responses, cellular growth, and apoptosis
(Aggarwal, 2004). NFκB can be activated by a number of factors including bacteria,
viruses, stress factors, mitogens, growth factors and hormones. EGFR is also able to
activate NFκB through Akt (Nakano, Shindo, Sakon, Nishinaka, Mihara, & Yagita,
1998). Finally, treatment related stresses such as chemotherapy and radiation can
suppress apoptosis through induction of NFκB (Sun & Andersson, 2002).
NFκB family members consist of five Rel (reticuloendotheliosis) domain-
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containing proteins: RelA (p65), RelB, c-Rel, p50/p105 (NFκB1) and p52/p100 (NFκB2).
Reticuloendotheliosis designates a group of pathologic syndromes in several avian
species caused by a retrovirus resulting in B and T lymphomas. Later the human genomic
sequence homologous to the avian strain was isolated and is used to describe a large
family of transcriptional regulators all of which contain a DNA binding domain, a nuclear
localization signal, dimerization domains and the IκB binding domain (Brownell,
O’Brien, Nash, & Rice, 1985; Shehata, 2005).
Two pathways predominate in NFκB activation, the classical or canonical
pathway and the noncanonical or alternative pathway. The common regulatory step in
both of these pathways is activation of the IκB kinase (IKK) complex consisting of the
catalytic kinase subunits (IKKα and/or IKKβ) and the regulatory protein NEMO (NFκB
essential modulator also known as IKKγ) (Tergaonkar, 2006). The IκB family consists of
seven nuclear proteins, three of which regulate transcription by interacting with NFκB
family members in the nucleus. The remaining IκB family members interact with NFκB
in the cytoplasm preventing its translocation to the nucleus. NFκB family members are
sequestered in the cytoplasm in their inactive state by IκB, NFκB1 p105 and NFκB p100.
NFκB/p65 consists of a heterotrimer of p50, p65 and IκB in the cytoplasm. The
degradation of IκB releases the heterodimer p50-p65 to travel to the nucleus and affect
gene transcription. This form is the most highly studied of the NFκB family members in
relation to carcinogenesis (Sun & Andersson, 2002). Cleavage of p100 produces p52;
whereas p105 is cleaved to form p50, thereby allowing NFκB activation through nuclear
translocation (Graham & Gibson, 2005).
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The IKK complex degrades IκB via the 26S proteasome. The 26S proteasome is a
multifunctional complex present in the cytoplasm of most eukaryotic cells that serves to
recognize degradation signals on certain proteins. Unneeded or damaged proteins are
marked for destruction by the cell and disassembled by the proteasome. The proteasome
also acts to control gene transcription by removing inhibitory molecules like IκB from
active forms of NFκB. Inhibitors of the proteasome, such as the drug bortezomib, can
prevent the activation of proteins like NFκB without causing undue harm to normal cells
(Schwartz & Davidson, 2004).
One of bortezomib’s mechanisms of action is attributed to its ability to
downregulate the PI3K/Akt pathway through increased proteasomal inhibition. Although
total protein expression levels of Akt remained unchanged after bortezomib treatment, the
activated phosphorylated form is significantly decreased after treatment in colon, lung
and squamous cell carcinoma cell lines (Cascone, Morelli, Morgillo, Kim, Rodolico,
Pepe et al., 2008). Despite bortezomib’s ability to decrease activated Akt, recent studies
demonstrate high levels of basal, phosphorylated Akt can overwhelm bortezomib’s
actions supporting a rationale for combination therapy using EGFR targeted agents in
conjunction with proteasome inhibitors to accomplish synergistic inhibition (McConkey
& Zhu, 2008).
IKKβ is the primary activator of IκB in the classical or canonical pathway
whereas IKKα activates RelB through the alternative or noncanonical pathway (Bonizzi
& Karin, 2004). RelB was once believed to be important only in B lymphocyte
development but has recently shown relevance in carcinogenesis through the inhibition of
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apoptosis (Allen, Saigal, Nottingham, Arun, Chen, & Van Waes, 2008). c-Rel as an
oncogenic driver is less well studied but may target other transcription factors related to
the inflammatory process. Constitutive activation of NFκB family members is common in
tumors as a mechanism of apoptotic evasion and increased cellular proliferation, making
it an attractive target for therapy (Pacifico & Leonardi, 2006).
Activation of the NFκB pathway through the ligand, tumor necrosis factor alpha
(TNFα) leads to activation of proteins that control cell survival, proliferation, migration
and resistance to chemotherapeutic agents (Jackson-Bernitsas, Ichikawa, Takada, Myers,
Lin, Darnay, et al., 2006). The TNF family of cytokines is produced by a wide variety of
cells within the immune system and is known for producing both antitumor and tumor
promoting activities. In mouse tumor models, TNFα demonstrates anti-tumor activity by
inducing a hemorrhagic necrosis and is believed to stimulate the lytic function of the
host’s inflammatory response. Lysis occurs through proteins known as complement,
causing the destruction of the cell membrane and subsequent release of its contents.
Although the liver is the primary site for complement synthesis, macrophages are induced
by cytokines such as TNFα to release components of the complement cascade during
infections (Carroll, 2004).
Tumor promoting activities of TNFα involve signaling that directly regulates the
expression of anti-apoptotic genes, stimulation of angiogenesis, tumor adherence and
cellular migration (von Biberstein, Spiro, Lindquist, & Kreutzer, 1995). TNFα is the most
potent activator of NFκB and is the primary ligand for the classical or canonical pathway
of NFκB (Hacker & Karin, 2006). The canonical pathway is stimulated by various
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immune receptors that lead to the activation of the IKK complex which in turn
phosphorylates and activates NFκB. The alternative pathway, although triggered by
immune receptors and TNF members as well, are affected by a more limited number of
ligands (Sun & Ley, 2008).
In addition to the roles that NFκB plays in inflammatory diseases, constitutive
activation of the NFκB pathway is involved in several cancers including head and neck.
Mostly it is thought that changes in the upstream pathways that lead to NFκB activation
become deregulated in cancer. Most of the activities mediated by TNFα are carried out by
tumor necrosis factor receptor 1 (TNFR1). TNFR1 can have opposing effects by
stimulating apoptotic and anti-apoptotic pathways. NFκB is a central factor in initiating
the transcription of proliferative proteins and anti-apoptotic signaling (Wang, Mayo, &
Baldwin, 1996). Cell survival pathways via TNFR1 involve the activation of transcription
factors via MAPK and cJun N-terminal kinase (JNK). TNFα can initiate opposing effects
through binding of its receptor TNFR1 and the recruitment of caspase-8, leading to
apoptosis. The noncanonical pathway is responsible for the activation of RelB and occurs
during the development of lymphoid organs. Only a small number of stimuli are known
to activate NFκB via this pathway including lymphotoxin, CD40 and receptor activator of
NFκB (RANK). This pathway also uses the IKK complex that comprises two IKKα
subunits, but not NEMO. In the noncanonical pathway, ligand- induced activation results
in the activation of NFκB-inducing kinase (NIK), which phosphorylates and activates the
IKKα complex (Bonizzi & Karin, 2005). For a summarized comparison of differences
between classical NFκB signaling versus alternative signaling see Table 1.
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Table 1. Summary of Classical (Canonical) NFκB Pathway Versus Alternative
(Noncanonical) Pathway.
Classical NFκB pathway
Stimulators

Activated
proteins

Targeted
Actions

Toll-like receptors
Interleukin-1 receptor
TNFR1 via TNFα
B-cell receptor
IκB kinase complex (IKK) composed
of IKKα, IKKβ and NEMO but
mostly dependent on IKKβ
NFκB (RelA/p65), c-Rel, NFκB1 is
activated to travel to nucleus
Cell survival
Part of normal development and
function of immune system

Alternative NFκB pathway
B-cell activating factor receptor
Lymphotoxin
CD40
RANK
NIK and IKKα
IKKα activates NFκB2/p100 to
produce p52 to travel to nucleus
(complexed with RelB)
Cell survival, activation and
proliferation
Regulation of lymphoid
organogenesis and development of B
and T lymphocytes

Normal cells rarely show constitutive NFκB activation except proliferating T and
B cells, thymocytes, monocytes and astrocytes (Aggarwal, 2004). NFκB is deregulated in
many cancers including head and neck, breast, non-small cell lung, thyroid, T and B-cell
lymphocyte leukemia and several virally-induced tumors (Chen, Castranova, Shi, &
Demers, 1999). NFκB further supports tumor- promoting activities through stimulation of
cell proliferation, inhibition of apoptosis and promotion of angiogenesis by encoding
cyclin-dependent kinases such as cyclin D1 (Aggarwal, 2004).
Aberrant Cell Cycle Machinery in HNSCCs
Individuals chronically exposed to carcinogens such as those found in tobacco
and ethanol are predisposed to genetic modifications leading to loss of cell cycle control.
Among the most common genetic abnormalities involve those in a family of cell cycle
regulators called cyclins. Cyclins regulate a cell’s progression from the G1 growth phase
into the S (synthesis) phase, contributing to proliferation and growth (Karin, Cao, Greten,
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& Li, 2002). These proteins were appropriately named because their concentration varies
in a recurrent fashion during the cell cycle. During the cell cycle, non-dividing cells exist
in a maintenance phase called G0 (resting phase). Once they have received the
instructions for division, they enter the G1 (gap) phase, the period when the cell grows
and prepares for division. In order to proceed to the actual division of cellular contents,
the cell must pass a restriction point in the G1 phase. Cells that do not pass this point may
re-enter G0, leave the cell cycle and cease dividing or die by the apoptotic pathway.
During G1 cellular contents are duplicated and cyclin D1 dominates. Before the cell can
proceed to synthesis, cellular damage is assessed at the DNA damage checkpoint where
p53 may arrest the cell cycle for repair or send the cell into apoptosis. During the S phase
chromosomes are duplicated and cyclins E and A predominate. During G2 the cell
prepares for division in the M phase of mitosis controlled by B cyclins. During G 0 the cell
may leave the cell cycle and quit dividing or die through the apoptotic pathway (Figure
2).

Figure 2. Cell Cycle Phases (perpendicular lines indicate inhibition).
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Apoptosis is induced by events such as growth factor withdrawal, toxins or DNA
damage. Survival functions are supported by preventing the release of pro-apoptotic
proteins from the mitochondria. If a cell is damaged beyond repair, apoptosis is initiated
through pro-apoptotic genes like B-cell lymphoma 2 (Bcl-2) associated X protein (Bax)
and downregulation of pro-survival genes like Bcl-2 (Partridge, Costea, & Huang, 2007).
The majority of Bax is found in the cytoplasm but when activated inserts itself into the
membrane of the mitochondria releasing the pro-apoptotic signaling molecules of the
caspase family. Within the mitochondria are cell death factors capable of initiating
apoptosis through the caspases. Caspases, or cysteine-aspartic proteases, play essential
roles in programmed cell death. The activation of the caspase cascade leads to
characteristic morphological changes in the cell including shrinkage, chromatin
condensation, DNA fragmentation and plasma membrane blebbing. Cells undergoing
apoptosis are eventually removed by phagocytosis. This process is in contrast to necrosis,
a form of cell death marked by swelling of the cell and eventual rupture (Pop & Salvesen,
2009).
Once past the restriction point, normal dividing cells enter S (synthesis) phase, a
period of DNA replication and chromosome duplication. During the M (mitotic) phase
the cell divides. G2 (gap) follows S phase allowing the cell to prepare for another round
of cell division by expanding cellular material and organelles. Cell cycle progression is
controlled by individual cyclins, D, E, A and B. Cyclins E and A control a cell’s
progression into synthesis while cyclin B controls the process of mitosis. Cyclin D family
members regulate the entry of cells into G1 from G0. The aberrant expression of cyclin
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D1 has been documented in several human cancers including head and neck and is
upregulated by growth factors (Kim & Diehl, 2009). Many cancers have determined ways
to hijack the cell cycle machinery by progressing through the DNA damage checkpoint
unimpeded (Collins, Jacks, & Pavletich, 1997).
Role of p53 in Cell Cycle Control
The p53 tumor suppressor gene is commonly involved in many human cancers
including head and neck. It plays an important role in arresting the cell cycle to allow
damaged DNA to be repaired or initiate apoptosis if repair is not possible. Stress signals
stimulate p53 to translocate to the nucleus and induce apoptosis, preventing damaged
cells from moving through the cell cycle and proliferating. Once in the nucleus, p53
binds DNA and activates expression of several genes involved in the cell cycle such as
p21(WAF1). P21 binds to and inhibits the activity of cyclin dependent kinase 2 (CDK2)
to regulate cell cycle progression, preventing the cell’s entry into the synthesis phase.
CDK2 is a subunit of the cyclin-dependent kinase complex and a known initiator of the
cell cycle. The expression of p21 is tightly controlled by p53 to prevent cell growth
(Junttila & Evan, 2009).
Inactivating mutations in p53 are found in many cancers, including head and
neck, with an overall prevalence of 50 percent. The overexpression of p53 is usually
indicative of the presence of mutant p53. The absence of p53 staining is typically
considered synonymous with a wild-type phenotype, although such a staining pattern
could also be explained by deletion of the gene. Overexpression of mutant p53 is capable
of downregulating the normal, tumor-suppressing activities of wild-type p53 (Theoret,
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Cohen, Nahvi, Ngo, Suri, Powell, et al., 2008). Without functional p53 actions, tumor
growth is allowed to progress unchecked and may contribute to upregulated NFκB
activity (Levine, 1997).
The proteasome inhibitor bortezomib has been shown to stabilize cell cycle
regulatory proteins like p53 in tumor cells. The resulting increased levels of activated p53
inhibits uncontrolled cell cycle progression and/or promotes apoptosis attributing
additional anti-tumor actions to bortezomib beyond just inhibition of NFκB (Schwartz &
Davidson, 2004).
Targeted Therapies in HNSCCs
Background
Targeted therapy refers to anticancer treatments which specifically target key
molecules or pathways of cancer cells aiming to stop the processes of cell growth and
metastasis. EGFR was the first receptor to be investigated for targeted cancer therapy,
known to be commonly overexpressed in a wide range of solid tumors including head and
neck. Targeted agents have been developed against EGFR and used clinically as
monotherapies, but their successful applications have been limited to a small population
of patients. Due to the complexity of signaling between multiple pathways, drug
combinations targeting several pathways are proposed to optimize treatment results
(Scaltriti & Baselga, 2006).
Gefitinib was one of the first tyrosine kinase inhibitors developed to block the
downstream pathways activated by EGFR through its primary ligands, EGF and TGFα,
resulting in increased cellular proliferation and survival. Gefitinib is proposed to block
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several downstream molecules that may potentially crosstalk with other pathways
(Cooper & Cohen, 2009). Although initially developed as a hematological cancer agent,
bortezomib is currently being investigated as a potential solid tumor agent. Bortezomib
seems to have a wide range of anti-cancer effects including stabilization of the cell cycle
regulator p53, upregulation of pro-apoptotic genes such as Bax and downregulation of
anti-apoptotic genes like Bcl-2 (Schwartz & Davidson, 2004). More selective targeted
agents such as bay 11-7082 are used in the laboratory to specifically target NFκB but
appear to be less effective than the broad-spectrum drug bortezomib (Gasparian,
Guryanova, Chebotaeve, Shiskin, Yemelyanov, & Budunova, 2009). The use of
combination agents aims to enhance current therapies as well as prevent the development
of treatment resistance.
Bortezomib and Bay 11-7082
Determining specific pathways of activation in the HNSCC patient population are
critical for designing combination therapies as each treatment agent has specific modes of
action. Bortezomib inhibits NFκB by preventing the proteasome from degrading IκBα
and the inhibitory domain of p100. The United States Food and Drug Administration
(FDA) approved bortezomib for use in multiple and mantle cell myeloma patients who
have received at least one prior therapy. PS-341 or bortezomib is the only proteasome
inhibitor in clinical development (Nencioni, Grunebach, Patrone, Ballestrero, & Brossart,
2007). Bortezomib’s toxicity is well tolerated and superior to high-dose glucocorticoids
in the areas of median time to progression, response rate, and survival in patients with
relapsed myeloma (Schwartz & Davidson, 2004). Glucocorticoids are steroid-based
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agents used clinically to suppress an overactive immune system. Because of their broadspectrum effects, they may impair a patient’s ability to overcome DNA damage and stress
produced by cancer progression and their associated treatments (Keith, 2008).
Proteasome inhibitors like bortezomib target proliferating cells which appear to be more
sensitive to the drug than non-dividing cells. This greater sensitivity is attributed to cell
cycle arrest caused by the proteasome which leads to eventual apoptosis of tumor cells.
Bortezomib not only induces apoptosis in cancer cells but sensitizes tumors to
chemotoxic and radiation therapies (Olivier, Robe, & Bours, 2006). Inhibition of the
proteasome is also postulated to initiate accumulation of the tumor suppressor p53 as will
as apoptotic proteins while decreasing NFκB expression (Schwartz & Davidson, 2004).
Bortezomib’s actions are multi-factorial as it can cause apoptosis in cell lines lacking p53
as well. The accumulation of misfolded proteins due to the inhibition of the proteasome
leads to cell death, attributing additional factors to bortezomib’s cytotoxic actions
(Kisselev & Goldberg, 2001).
NFκB is a well-characterized molecule involved in treatment resistance and is
believed to be the main target of bortezomib, although data suggests proteasome
inhibitors have additional cytotoxic targets. When cell cycle progression is inhibited in
cells treated with bortezomib, the levels of caspase increase contributing to higher levels
of apoptosis (Allen et al., 2008). In order to further define on target and off-target effects
of bortezomib, targeted inhibitors have been employed to assess the efficacy of
specifically inhibiting NFκB. Bay 11-7082 is a specific NFκB inhibitor that primarily
targets the activating IKK complex, in particular IKKβ (Figure 3).
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Figure 3. Targeted Agents in the NFκB and EGFR pathways.
Agents targeting several pathways in tumor growth are potentially effective
against treatment resistance. Cross-talk between pathways like NFκB and EGFR requires
modulation of multiple downstream markers with broad scope inhibitors such as gefitinib
and more specific targeted agents like bortezomib. Bay 11-7082 and bortezomib act to
block pathways of resistance such as the canonical and noncanonical pathways of NFκB.
Bortezomib further helps to stabilize tumor suppressors like p53 and increase proapoptotic proteins like Bax and decrease anti-apoptotic proteins such as Bcl-2. To date,
IKK inhibitors remain in the preclinical stage of testing to determine their efficacy as
therapeutic agents. Recent studies in cell lines have demonstrated a broader and more
potent cell killing effect from proteasome inhibitors over IKKβ specific inhibitors
(Gasparian, et al., 2009).
Bortezomib acts in a specific and reversible manner to target the proteasome and
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promote tumor cells to become apoptotic (Adams, Palombella, Sausville, Johnson,
Destree, Lazarus, et al., 1999). Several clinical studies are currently underway to
determine if combinations of bortezomib with conventional chemotherapy and/or
radiation will benefit HNSCC patients. Further understanding of bortezomib’s effects in
HNSCC tumor tissues is necessary and at this point has only been effectively addressed
in hematological malignancies (Montagut, Rovira, & Albanell, 2006; Nencioni et al.,
2007).
Gefitinib
EGFR targeted treatments like gefitinib inhibit cell proliferation through
intracellular competitive binding of the tyrosine kinase domain of the receptor (Mandic,
Rodgarkia-Dara, Zhu, Folz, Bette, Weihe et al., 2006). Gefitinib (Iressa® ZD1839) is a
small, oral EGFR tyrosine kinase inhibitor that prevents the activation of EGFR and any
downstream signals triggered by its phosphorylation (see Figure 3). Tyrosine kinase
inhibitors have the potential benefit of cross reactivity between EGFR and other receptors
of the same family such as the HER receptors due to their nonspecific reactivity towards
the ATP site of tyrosine kinases (Dassonville, Bozec, Fischel, & Milano, 2007). Gefitinib
was approved by the FDA in 2004 as a monotherapy for patients with locally advanced or
metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel
chemotherapeutic regimens. In phase I-II studies, gefitinib showed low toxicity and
efficient anti-tumor activity in solid malignant tumors including HNSCCs (Erjala,
Raitanen, Kulmala, & Grenman, 2007). Since June 2005, gefitinib was withheld from
United States markets for use in patients with non-small cell lung cancer refractory to
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previous platinum-based chemotherapy as the result of negative phase III trial results.
These results were unable to show the drug’s efficacy in improving survival rates for
these patients. Gefitinib continues to be tested as a monotherapy and combination
regimen for HNSCC patients, although clinically relevant responses are limited in the
majority of head and neck tumors (Cooper & Cohen, 2009). It appears to be well
tolerated with a number of current therapies such as cisplatin, carboplatin, paclitaxel,
taxanes, doxorubicin and radiotherapy. In a single agent trial, an overall response rate of
10.6% was achieved with gefitinib in 47 assessable HNSCC patients (Cohen, 2006). A
recent study combining gefitinib with chemoradiotherapy in advanced stage HNSCC
patients saw a negligible increase of 3% in survival rates over chemoradiotherapy alone
(Hainsworth, Spigel, Burris, Markus, Shipley, Kuzur, et al., 2009). Efficient
combinations and drug schedules continue to be explored using tyrosine kinase inhibitors
in advanced stage head and neck patients.
Targeted agents designed to block only one pathway in most HNSCCs will result
in decreased treatment efficiencies or the development of drug resistance, suggesting that
effective therapy will require a combination of agents. By combining agents such as
bortezomib and gefitinib aimed at multiple pathways, greater response rates are expected
in patients presenting with limited treatment options.
Summary
Although advanced treatments have improved a head and neck patient’s quality of
life, the survival rate has not improved over the past several decades. The ability to
classify a patient into specific treatment responsive categories continues to be a
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challenge. Advances in genomics have improved the understanding of the processes
governing head and neck cancer and have indentified major pathways of deregulation.
Two of these deregulated pathways, NFκB and EGFR are predicted to provide
downstream molecular markers relevant to determining treatment response in these
patients. Further characterization of these pathways is required to define those patients
most likely to respond to targeted therapies.
Statement of Problem
Despite the overexpression of EGFR and NFκB in head and neck cancers, the use
of targeted inhibitors as single agents has shown minimal success. A combined treatment
regimen using an EGFR pathway inhibitor, gefitinib, and an NFκB pathway inhibitor,
bortezomib, is expected to demonstrate improved cellular toxicity over single agent
treatment in HNSCC cell lines. The use of EGFR inhibitors with other targeted therapies
show promise for extending patient survival and reducing toxicities but further data is
needed to establish the correct drug combinations as well as a potentially responsive
patient population. This study characterized the deregulated pathways of EGFR and
NFκB in a subset of HNSCC patients with EGFR gene amplification in order to assist the
clinician in determining the best course of treatment.

CHAPTER 2: LITERATURE REVIEW

Only a small number of patients with HNSCC respond to EGFR-directed
therapies due to the lack of predictive markers for selecting the right patients and
applying the correct combination of pathway-directed treatments. EGFR expression
status alone may not be predictive of anti-EGFR inhibitor response in head and neck
patients. While elevated EGFR protein expression correlates with poorer survival in
many cancers including head and neck, the underlying molecular mechanisms associated
with EGFR gene copy number in advanced stage head and neck patients remains
unexplored. The deregulation of multiple pathways such as EGFR and NFκB present a
challenging obstacle to overcoming treatment resistance. Bortezomib has so far
demonstrated efficiency as an NFκB inhibitor in hematological cancers and may
potentially hold promise in solid tumors. The use of EGFR inhibitors like gefitinib with
bortezomib show promise for combating resistance, but further data is needed to establish
appropriate patient selection and treatment combinations.
Background
EGFR is commonly expressed at high levels in epithelial tumors, including head
and neck carcinomas. This increased activity results in enhanced cellular proliferation
and survival (Arteaga, 2002). Excessive activation of EGFR can occur from several
mechanisms including increased synthesis of the receptor, receptor-activating mutations,

27

28
decreased degradation of EGFR protein, and amplification of the EGFR gene (Franovic,
Gunaratnam, Smith, Robert, Patten & Lee, 2007). The rationale for targeting this receptor
is substantial and has lead to the development of agents blocking activation of EGFR like
gefitinib. Unfortunately, EGFR inhibitors as a monotherapy have produced lower
response rates than expected in advanced stage tumors (Dassonville et al., 2007). In a
subset of head and neck tumors, EGFR is activated by gene amplification; and
multivariate analysis has shown amplification is a significant and unfavorable predictor
for overall survival in head and neck patients (Temam, Kawaguchi, El-Naggar, Jelinek,
Tang, Liu et al., 2007).
Existing data suggests that amplification and overexpression of the EGFR gene
may be a useful diagnostic and prognostic marker in advanced stage HNSCCs. The
underlying molecular mechanisms contributing to the deregulation of EGFR require
further investigation in order to focus targeted treatments towards a responsive patient
population as current therapies remain largely ineffective. Although poorer patient
prognosis is known to be associated with EGFR gene amplification in HNSCC patients,
what this means for optimal treatment regimens remains to be determined. Gefitinib has
been determined to be effective against EGFR amplified tumors in vitro but is showing
limited success in patient centered clinical trials (Cooper & Cohen, 2009). Unimpressive
in vivo results are leading the search for combination agents to augment the cytotoxic
effects of anti-EGFR therapies like gefitinib. Bortezomib is a potential combination agent
that may complement gefitinib’s cytotoxic actions without adding significant overlapping
toxicities. Bortezomib is still being explored as a viable treatment agent in solid tumors
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as both a monotherapy as well as in combination with current targeted therapies. A multifaceted drug, bortezomib continues to demonstrate a wide-range of cytotoxic abilities that
may enhance the already more characterized tyrosine kinase inhibitor gefitinib (Weber,
Cerniglia, Maity, & Gupta, et al., 2007). Targeted patient selection with combination
treatments focused on multiple pathways of deregulation are proposed to overcome
treatment resistance and achieve better patient outcomes (McCarty & Block, 2006).
Common Laboratory Assays for DNA, RNA and Protein Measurement
Gene amplification is a cellular process in which multiple copies of a gene are
produced. The result is an amplification of the phenotype or expressed trait associated
with the gene, for example the epidermal growth factor receptor which can be measured
by the polymerase chain reaction (PCR) or fluorescent in situ hybridization (FISH).
There may also be an increase in the protein made from that gene which can be measured
by immunohistochemistry (IHC) in tissue specimens or by western blot analysis in
cellular extracts (Killeen, 2003).
Gene amplification is common in cancer cells, and some amplified genes may
cause cancer cells to grow or become resistant to anticancer drugs (Wells, 2007).
Quantitative polymerase chain reaction or qPCR is a method that allows the estimation of
the amount of a given DNA sequence present in a sample. Real-time PCR is an
established tool for DNA quantification that measures the accumulation of DNA product
after each round of PCR amplification in “real time.” Real-time PCR is based on the
detection of fluorescence produced by a reporter molecule which increases, as the
reaction proceeds. This occurs due to the accumulation of the PCR product with each
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cycle of amplification. These fluorescent reporter molecules include dyes such as
SYBR®Green that bind to the double-stranded DNA of the target which is monitored as
the reaction is occurring in real time. Real-time PCR can be used to compare (control)
samples like HaCaT cells, skin keratinocytes that express normal levels of EGFR to
experimental cell samples, giving an idea as to expression changes in the EGFR gene.
qPCR is considered the gold standard in gene amplification techniques, often applied to
quantitatively determine levels of gene expression in tissue samples, cell culture or fluids
(Derveaux, Vandesompele, Hellemans, 2010; Sisti, Guescini, Rocchi, Tibollo, D'Atri,
Stocchi, 2010, Wells, 2007).
In tissue biopsies, gene amplification is effectively measured by fluorescence in
situ hybridization (FISH). Tissue samples recovered during surgical removal are fixed in
formaldehyde and processed into paraffin blocks for storage in the clinical pathology
laboratory. This provides a convenient medium for analysis in the laboratory as biopsies
are commonly stored as paraffin blocks and fluorescent EGFR probes are commercially
available. The use of fluorescently labeled probes in the FISH assay allow for precise
identification of gene amplification within the tumor in relation to the surrounding tissue
morphology (Martin, Mazzucchelli, & Frattini, 2009).
Protein expression is commonly measured in tissue biopsy specimens in the
laboratory by an immunohistochemistry (IHC) assay using antibodies against a known
antigen expressed in the tissue. As in the FISH assay, the advantage of assessing protein
expression in tissue specimens allows for assessment of tissue morphology as a whole
(Eastmond, Schuler, & Rupa, 1995). Expression levels of EGFR downstream pathways
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are commonly measured by IHC. For instance, the phosphorylation status of Akt, STAT
and MAPK can be effectively measured in tissue biopsy specimens using this technique
(Agulnik, Santos, Hedley, Nicklee, dos Reis, et al., 2007; Pernas, Allen, Winters, Yan,
Friedman, Dabir, et al., 2009).
For determining protein expression levels in cell culture, western blotting
methods are used. Cells are lysed to release their contents then the corresponding protein
samples are run on a gel which separates the proteins on the basis of size. These gel
proteins are transferred onto a membrane using electricity. This membrane is then probed
for proteins of interest using antibodies (Gallagher & Chakavarti, 2008). Quantitative
comparisons can be made between samples after normalization to a loading control. βactin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) are highly conserved
proteins present in all eukaryotic cells commonly used to confirm protein integrity and
equal loading of protein samples in a western blot gel (Killeen, 2003).
Gene Amplification in HNSCCs
Several studies suggest response to the targeted agent gefitinib may depend on the
level of expression of EGFR in the tumor. Although EGFR protein expression is
commonly found in head and neck tumors, EGFR protein levels have failed to predict
gefitinib sensitivity in head and neck tumors by IHC analysis or immunoblotting (Pernas
et al., 2009). On the other hand, the prognostic significance of EGFR gene
overexpression in head and neck tumors is linked to a poor prognosis and may be
correlated with gefitinib response in head and neck tumors. Chung et al showed
decreased survival in HNSCC patients with EGFR gene amplification as compared to
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tumors classified as normal in EGFR gene expression. EGFR amplified groups
experienced worse progression free survival at 18 months compared with 25 months for
the control group. Overall survival was 20 months for EGFR gene amplified patients
versus 29 months for negative patients. Fifty of the 86 specimens were surveyed for
EGFR protein expression by IHC, although no correlation was found between protein
expression and gene expression of the receptor (Chung, Ely, McGavran, Varella-Garcia,
Parker, Parker, et al., 2006).
EGFR gene amplification generally results in increased protein expression,
although differences in the prevalence of EGFR overexpression reported by different
studies may be due to variations in techniques and type of antibodies used in IHC, criteria
for determining overexpression and interobserver variability (Kersting, Packeisen,
Leidinger, Brandt, von Wasielewski, Winkelmann, et al., 2005). Braut et al found 16% (8
of 50 total samples) of biopsied laryngeal tumors to contain amplification of the EGFR
gene by FISH. Immunohistochemical analysis indicated a signficantly higher protein
expression of EGFR in all 8 biopsies as compared to control samples without EGFR gene
amplification (Braut, Krstulja, Kujundzic, Manestar, Hadzisejdic, Jonjic, et al., 2009).
Sheu et al also demonstrated a high correlation between EGFR amplification and EGFR
protein expression in oral squamous cell carcinomas. Using PCR and FISH analysis,
multiple DNA copies of the EGFR gene were noted in 90% of tumors (18 of 20). Each of
these EGFR amplified tumors displayed strong positive IHC staining indicating a high
level of corresponding protein expression by the receptor (Sheu, Hua, Wan, Lin, Lai,
Tseng, et al., 2009).
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Temam et al reviewed 134 HNSCC specimens graded as well, moderately or
poorly differentiated for EGFR gene expression by fluorescent in situ hybridization
(FISH) and EGFR protein expression by IHC and found 24% of tumors with an atypical
EGFR gene copy number. Twenty-two tumors had an increased gene copy number while
10 tumors had a decreased copy number. Tumors with abnormal gene copy numbers
correlated significantly with increased lymph node metastasis and advanced pathologic
stage. Patients with abnormal gene copy number also exhibited significantly worse
overall, cancer-specific and disease-free survival times compared to patients with normal
EGFR gene copy numbers. However, IHC results did not show a significant correlation
between EGFR protein expression and gene copy number. This could be the result of a
limited amount of data, as only 12% of tumors were used to assess protein expression by
IHC (Temam et al., 2007). The correlation between EGFR gene copy number, protein
expression and patient prognosis in advanced stage head and neck carcinomas require
further study in order to assist in patient selection for EGFR directed therapy.
EGFR Targeted Therapeutics
Introduction
EGFR overexpression is found in approximately 90% of head and neck tumors,
although this prevalence has not been definitively correlated with EGFR inhibitor
sensitivity (Cooper & Cohen, 2009). Current therapeutic trends focus on the development
of novel agents specifically targeting those growth factor pathways that are deregulated in
tumor cells and using them in conjunction with traditional palliative regimens. As single
agents, EGFR inhibitors have shown success in 4 to 17% of patients but these
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percentages increase when used in combination with radiation to 10 to 26% (Chung, Ely,
et al., 2006). Combination strategies using traditional therapies such as radiation and
chemotherapy with gefitinib demonstrate some clinical value but negative results from
large scale phase III clinical trials in both lung and head and neck cancers have caused
investigators to continue the search for optimal treatments (Huang, Armstrong,
Benavente, Chinnaiyan, & Harari, 2004; Siu, Soulieres, Chen, Pond, Chin, Francis et al.,
2007). The selection of head and neck patients for combination therapies is especially
important to maximize response rates and significantly increase survival times.
Determining anti-EGFR treatment efficiency or resistance in advanced stage
tumors may depend on the exact pathway of activation; therefore, identifying and
characterizing these abnormal downstream signaling molecules will be critical. The
optimal administration and treatment schedule of EGFR inhibitors may also require
optimization for this subset of patients. The most clinically advanced anti-EGFR
therapies, monoclonal antibodies and tyrosine kinase inhibitors, target the EGFR
extracellularly and intracellularly, resulting in different routes of EGFR pathway
blockade. Cetuximab blocks ligand binding of the EGFR extracellularly, triggering
receptor internalization and breakdown, ultimately resulting in downregulation in the
number of EGFRs on the cell surface. All tyrosine kinase inhibitors act intracellularly to
prevent downstream signaling by EGFR without causing the receptor’s internalization or
degradation. Together the combination of the two modes of therapy can inhibit cell
proliferation and enhance tumor cell toxicity to improve long term survival (Rocha-Lima,
Soares, Raez, & Singal, 2007).
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Matar et al studied the in vitro effects of the tyrosine kinase inhibitor gefitinib and
the monoclonal antibody cetuximab in a panel of carcinoma cell lines with varying levels
of EGFR from medium to high. The possibility of additive effects between gefitinib and
cetuximab were determined by combining both EGFR inhibitors on each cell line.
Cetuximab was found to exhibit a plateau effect at the maximum dose of 10nmol/L. A
synergistic effect was found with the addition of gefitinib at 0.1, 1 and 10µmol/L doses to
0.01µM of cetuximab in high-EGFR expressing A431 cells. Gefitinib was not found to
have a plateau effect possibly due to its nonspecific kinase inhibitory effects. These
authors further investigated the effects of combining inhibitors on the phosphorylation of
EGFR, MAPK and Akt by western blot analysis. A431 cells, a human epithelial
carcinoma line expressing high levels of EGFR, were exposed to different concentrations
of cetuximab and gefitinib for two hours either alone or in combination demonstrating a
decrease for each signal transduction marker. A greater decrease was evident for the
combined treatment of both agents using 1 µmol/L gefitinib and 0.005 µmol/L cetuximab
over either agent alone (Matar, Rojo, Cassia, Moreno-Bueno, Di Cosimo, Tabernero, et
al., 2004). The data presented suggest that combining a diverse set of inhibitors may lead
to a more significant clinical response.
Data regarding tyrosine kinase inhibitors in head and neck tumors is more limited
in comparison to lung carcinomas for which gefitinib is currently approved for third line
treatment. Striking differences exist between non-small lung cancer studies and head and
neck tumors as studies reveal that lung cancer patients with EGFR gene amplification
respond significantly to EGFR tyrosine kinase inhibitors. Variable sensitivities to
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tyrosine kinase inhibitors such as gefitinib and erlotinib are noted in head and neck
cancers. Due to the similar etiologies between lung and HNSCCs, treatment options for
these two EGFR overexpressing carcinomas often follow a similar course in the
literature, although variable results are reported owing to the genetic complexity between
these epithelial tumor types. Mutations in the tyrosine kinase domain of the EGFR are
indicative of gefitinib sensitivity and are more prevalent in non-smoking, Asian females
with pulmonary adenocarcinomas. Similar tyrosine kinase domain mutations are rarely
found in head and neck patients, thereby limiting a potentially gefitinib-responsive
patient population (Varella-Garcia, 2006). Despite the disparities in tumor phenotypes,
head and neck tumors are under investigation to determine if biomarkers of gefitinib
sensitivity can be determined and correlated with EGFR gene copy status and prognosis.
Response to Tyrosine Kinase Inhibitors
Agulnik et al conducted a biomarker study of patients with recurrent or metastatic
head and neck cancer showing better response rates to the tyrosine kinase inhibitor
erlotinib in patients with high gene copy number versus low EGFR gene copy number.
Erlotinib is similar in action to gefitinib, blocking the ATP binding site of the tyrosine
kinase domain of EGFR. Agulnik et al used FISH to assess EGFR gene copy number in
32 head and neck tumor samples. Patients were designated FISH positive based on gene
amplification and high polysomy (multiple chromosomes) or negative in all other
categories. IHC analysis was used to assess protein expression of total and
phosphorylated EGFR, -ERK, -AKT and STAT3 for evaluation of changes in EGFR
pathway activation before and after a seven day erlotinib treatment. Ki67 was also
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evaluated as a marker of proliferation, phosphorylated p27 to assess cell cycle inhibition,
and phosphorylated NFκB for evaluation of NFκB pathway activation. Patients whose
tumors showed decreases in phosphorylated EGFR and phosphorylated NFκB after
erlotinib treatment were significantly associated with improved time to disease
progression and overall survival. A decrease in p27 (a cell cycle inhibitor) protein after
treatment was associated with an increase in time to disease progression and decreased
overall survival. The decrease in p27 was an unexpected finding as cell cycle arrest is a
typical response to tyrosine kinase inhibitors. A benefit of combined inhibition may result
from targeting those cells that continue to proliferate by using additional cytotoxic agents
rather than the use of monotherapies. Although FISH values were not statistically
significant, this study was the first to suggest a possible association between increased
gene copy number in head and neck cancers and response to the tyrosine kinase inhibitor
erlotinib (Agulnik et al., 2007).
Gefitinib
Gefitinib inhibits the EGFR tyrosine kinase domain and is presently used in the
treatment of locally advanced or metastatic non-small cell lung cancer. There is currently
no reliable predictive factor for response to therapy with EGFR inhibitors like gefitinib in
head and neck cancer. Lung cancer patients responsive to EGFR tyrosine kinase
inhibitors are those with mutant tyrosine kinase domains and/or those with tumors
dependent on EGFR phosphorylation for proliferation and metastasis as opposed to just
receptor amplification or mutation (Rogers, Box, Chambers, Barbachano, Nutting, RhysEvans, et al., 2009). Other predictive factors are being considered for head and neck
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tumors as similar mutations are rare and EGFR activation levels demonstrate variable
results.
Sebastian et al studied gefitinib effectiveness in a panel of 14 head and neck cell
lines from various locations including the larynx, oral cavity, tonsil and hypopharynx. A
three day dose schedule of gefitinib was not able to modulate total EGFR expression in
these cell lines as expected for an intracellular receptor inhibitor but a slight blockage of
the cell cycle was demonstrated after treatment with a resulting variable reduction in
phosphorylated Akt expression. Those cell lines with apparent signaling through
phosphorylated Akt tended to respond to gefitinib. Gefitinib was able to affect
downstream signaling with a 30 to 100% decrease in activated Akt. Six of 13 head and
neck cell lines with measurable phosphorylated Akt at baseline showed complete loss of
activity after gefitinib treatment of 1.9 – 5.4μM over 72 hours. Gefitinib’s effect on
MAPK was markedly less as five of 11 cell lines with detectable baseline expression
maintained at least 80% of the protein’s expression after treatment. The two highest
EGFR expressing cell lines, HNC-211 and HNC-199 demonstrated variable sensitivity
with IC50 values of 0.064μM and one of the highest IC50 values of 9.3μM, respectively,
after 72 hours of treatment, indicating receptor expression status is not predictive of
gefitinib response. Genomic analysis was not able to identify any activating mutations in
the kinase domain of these cell lines (Sebastian, Azzariti, Accardi, Conti, Pilato,
LaCalamita, et al., 2008). Heterogeneity in anti-EGFR inhibitor responses among cell
lines and patients is attributed to the current lack of consistent markers able to identify a
responsive population. Various clinical trials using gefitinib alone or in combination with
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standard therapies continue to demonstrate variable responses to treatment (Modjtahedi &
Essapen, 2009).
Pernas et al further defined gefinitib’s actions in a panel of four head and neck
cell lines consistent with the results of Sebastian et al showing that EGFR expression
status alone is not predictive of gefitinib response. Pernas et al compared two cell lines,
UMSCC-11A and UMSCC-11B, with high constitutive levels of EGFR to UMSCC-6
and UMSCC-9, two cell lines with intermediate to low levels of receptor expression. As
expected, gefitinib was unable to affect total EGFR protein expression in any of the cell
lines tested after a 5 day treatment. The UMSCC-11B cell line, a high EGFR expressing
cell line, was most resistant to gefitinib treatment, almost 10-fold that of the remaining
cell lines with an IC50 of 17μM.UMSCC-11B also demonstrated the highest levels of
basal pSTAT3 activity, although gefitinib was able to reduce these levels in a dose
dependent fashion. While NFκB p65 was inducible in UMSCC-6, UMSCC-11A and 11B through EGF ligand stimulation, gefitinib was not able to significantly decrease
NFκB expression in the UMSCC-11B cell line. Similar to the findings presented by
Sebastian et al, this study was unable to determine gefitinib sensitivity by EGFR
expression status alone, although the activated, phosphorylation status of the receptor
proved to be informative. UMSCC-9 exhibited the greatest response to gefitinib and the
highest level of EGFR phophorylation at the Tyr1068 site of the receptor. Tyr1068
mediates Akt signaling, a consistent finding with Sebastian et al who found activated Akt
levels to be indicative of a gefitinib response (Pernas et al., 2009).
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Bortezomib
Bortezomib has been approved by the FDA in the treatment of multiple myeloma.
Bortezomib’s efficiency as a monotherapy in various solid tumors is being investigated.
Noted toxicities from bortezomib treatment include diarrhea, vomiting and
peripheral neuropathy that significantly increase with rising dosages. Bortezomib acts in
a specific and reversible manner to target the proteasome and promote tumor cells to
become apoptotic. One of bortezomib’s mechanisms of actions is attributed to its ability
to downregulate the PI3K/Akt pathway and NFκB. NFκB’s activation is regulated by a
family of inhibitory proteins called IκBs. When phosphorylated, IκBs become targeted
for degradation by the proteasome, a multifunctional protein involved in removing
damaged or misfolded proteins, governing regulatory tasks of the cell cycle, transcription
factor activation, apoptosis and cell trafficking (Adams et al., 1999).
Allen et al. used DNA binding assays to assess bortezomib’s ability to inhibit
RelA in the head and neck cell lines UMSCC-9, UMSCC-11A and UMSCC-11B.
Bortezomib was able to suppress TNFα-induced RelA in the three cell lines, although
baseline constitutive activation of RelA was not affected by either 0.01µM or 0.1µM
dosages over 12 or 24 hours. Interestingly, bortezomib had a decreased effect on other
Rel subunits, including RelB, c-Rel and p52. All Rel subunits except c-Rel in both head
and neck tumor specimens and cell lines demonstrated increased nuclear expression by
IHC and DNA binding respectively. Bortezomib was not as effective at inhibiting nuclear
expression of Rel subunits in the three cell lines through the noncanonical pathway as
measured by DNA binding assay. Variable sensitivity to bortezomib was determined for
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the three cell lines using the (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, a tetrazole) MTT assay. Only UMSCC-11B showed sensitivity to bortezomib in
the range of 0.01-1μM over a 5 day drug exposure (Allen et al., 2009). Sensitivity ranges
in Allen et al.’s study were based on concentrations achieved in patient serum from
previous studies conducted by Papandreou et al. Phase III trials established the efficacy
of bortezomib at 1.3mg/m2 administered by intravenous injection on days 1, 4, 8, and 11
of a 21-day cycle for a maximum of eight cycles in patients with relapsed/refractory
multiple myeloma (Papandreou, Daliani, Nix, Yang, Madden, & Wang, 2004). Based on
these findings by Allen et al, potential signaling through the noncanonical pathway in
head and neck cancers supports the use of combination agents like gefitinib that may
target Akt and downstream RelB activation.
To evaluate bortezomib’s ability to downregulate the PI3K/Akt signaling
pathway, Weber et al used the head and neck cell line SQ20B which has constitutively
active expression levels of EGFR that results in upregulation of Akt. The cells were
treated with 0.0005, 0.001, 0.01, 0.1 and 1μM bortezomib. Protein was harvested 2, 4, 8
and 24 hours after treatment and analyzed by western blotting. Downregulation of Akt
was evident at 0.001μM, but 0.01μM was sufficient for almost complete down regulation
of phosphorylated Akt protein expression after 24 hours. Although bortezomib has been a
standard single agent treatment in hematological cancers, its efficiency as a dual agent in
solid tumors awaits further investigation (Weber, Cerniglia, Maity, & Gupta, 2007).
Ooi attempted to characterize bortezomib’s broad cytotoxic actions in the context
of p53 stabilization using multiple myeloma and epithelial tumor cells. By comparing the
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response of bortezomib-sensitive multiple myeloma cells to bortezomib-resistant solid
tumors such as breast, prostate, colon, and thyroid, these authors sought to characterize
how bortezomib increases protein levels of p53. The ubiquitin ligase human double
minute 2 (Hdm2) promotes the degradation of p53 by tagging the protein and marking it
for degradation by the proteasome. Once ubiquinated, p53 remains in the cytoplasm and
becomes transcriptionally inactive. Although p53 levels may increase as a result of
bortezomib’s inhibition of the proteasome, the ability of the tumor suppressor p53 to
affect the cell cycle becomes impaired. These authors were able to sensitize previously
bortezomib-resistant tumors with the addition of an Hdm2-inhibitor nutlin-3 (Ooi,
Hayden, Kotoula, McMillin, Charalambous, Daskalcki, et al., 2009). These results also
provided evidence for bortezomib’s cytotoxic actions being independent of p53 status.
Combaret et al studied a panel of twelve neuroblastoma cell lines and found p53
mutational status to be independent of bortezomib response. After a 72 hour treatment
with 0.01μM bortezomib, the accumulation of p53 protein was observed in all cell lines
by western blot irrespective of sensitivity or resistance to the drug. An exploration for the
involvement of other proteins involved in bortezomib resistance demonstrated high pretreatment and post-treatment expression of phosphorylated HSP27 (heat shock protein), a
group of proteins frequently upregulated as part of the stress response, in the two resistant
cell lines, CLB-Sedp and SHEP (Combaret, Boyault, Iacono, Brejon, Rousseau, &
Puisieux, 2008). In sensitive cell lines, bortezomib has been shown to stimulate p53
translocation to the nucleus in a time and concentration dependent manner as measured
by DNA binding assays (Williams & McConkey, 2003).
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Dual Blockage of EGFR and NFκB Pathways
The activation of EGFR and its downstream signal transduction kinases is known
to modulate tumor development, progression and therapeutic resistance, suggesting that
targeting common pathways may be essential for optimal inhibition. The activation of
these intermediaries has been implicated in the upregulation of NFκB, which has been
described in many cancer cell types as a supporter of tumor invasion, metastasis and
proliferation. Bancroft et al examined the effects of the EGFR inhibitor PD153035, the
anti-EGFR antibody C225, MEK (EGFR downstream effector) inhibitor U0126 and Akt
inhibitor LY-294002 in human head and neck cell lines on NFκB and AP-1 activation.
AP-1 or activator protein, is elevated in response to injury, cytokines and growth factors.
Using luciferase reporter gene constructs, UMSCC-9 and UMSCC-11B HNSCC cell
lines, were used to demonstrate basal NFκB and AP-1 activity. Upon pre-incubation with
the EGFR inhibitor PD153035, greater than 50% of NFκB and Ap-1 basal activity was
blocked. The anti-EGFR antibody C225, similar in action to cetuximab, significantly
inhibited EGF inducible Ap-1 reporter activity by 50%. NFκB inhibition was not
significant. Most notably the combination of the PI3K inhibitor and MEK inhibitor
resulted in greater inhibition of constitutive and EGF-inducible NFκB activity than either
agent alone. These authors found the MEK pathway, member of the MAPK pathway, was
an important contributor to the activation of AP-1, whereas the PI3K/Akt pathway
predominantly led to the activation of NFκB (Bancroft et al., 2002). As phosphorylation
of PI3K leads to Akt activation, the Akt pathway as supporter of apoptotic resistance
through NFκB provides a key mechanism in oncogenic EGFR signaling.
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Piperdi et al studied the effects of combining bortezomib and erlotinib in a panel
of NSCLC cell lines as these two agents have shown clinical activity with no overlapping
toxicities. Seven NSCLC cell lines (H322, H358, H661, H460, H522, H1299, and A549)
were used to evaluate the growth inhibitory activity by (MTT)-tetrazolium dye assay.
Cells were treated with either erlotinib or bortezomib, alone or in combination, given
either together or successively 24 hours apart. Cells were harvested at 48 hours from first
drug exposure. Only two of the seven cell lines tested had IC50 levels indicating
sensitivity to erlotinib at ≤ 1.46μM doses. Bortezomib had a narrower range of activity
with IC50 levels of 0.01μM to 0.066μM. For further study, two erlotinib sensitive cell
lines, H322 and H358, were chosen and two resistant, A549 and H1299. In two of the
four cell lines tested, H322 and A549, the cytotoxic effect from combining erlotinib and
bortezomib was neither synergistic nor additive. Cell survival was measured by colony
count and expressed as a fraction compared with baseline. The percentage of apoptosis
was measured by flow cytometry. Although cellular toxicity and cell death was not
significantly affected by combination treatment in 50% of the cell lines tested, increased
cytotoxicity and apoptosis were discovered after 72 hours in the H358 cell line. H358
cells were exposed to 0.05μM bortezomib in combination with 2μM erlotinib. The
schedule of drug dosage produced varying effects in the H358 cell line with the preexposure of elotinib abrogating the effect of bortezomib and synergistic effects with
concomitant dosing or bortezomib pre-exposure (Piperdi, Ling, & Perez-Soler, 2007).
Due to the selective action of erlotinib, additional studies are necessary to determine the
efficiency of combination treatments using different cell lines and tissue types.
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Summary
EGFR is highly expressed in most human head and neck cancer tumors. Despite
the prevalence of the receptor, single agent EGFR inhibitors continue to demonstrate
variable responses in HNSCCs. In order to further classify those patients that may
respond to EGFR inhibitors versus nonresponders, markers of treatment resistance are
continually being investigated. Studies have not been able to correlate EGFR protein
expression status to anti-EGFR inhibitor sensitivity. EGFR gene amplified tumors are a
subset of HNSCCs that demonstrate highly aggressive characteristics leading to
decreased progression-free and overall survival rates and may harbor certain deregulated
pathways that contribute to the resistance of currently employed treatments. Growth
factor receptors such as EGFR have the potential to increase NFκB expression through
Akt, contributing to the inefficiency of targeted treatments.
Differences in downstream pathways exist between head and neck tumors,
although the defining phenotype that determines the optimal treatment regimen is not yet
available. Downstream signal molecules may hold the key as cell lines that use Akt
signaling have been shown to be gefitinib sensitive, although its overexpression may be
an indicator of resistance. Bortezomib’s primary target is NFκB, although the drug’s
ability to effectively downregulate all NFκB family members remains in question. NFκB
overexpression has been proposed as a marker of treatment resistance through both
classical and alternative pathways. Combination drug schedules using bortezomib with
anti-EGFR inhibitors demonstrate promise in suppressing multiple deregulated pathways,
although the optimum dose schedule requires further examination.
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Significance of Study
HNSCCs represent a diverse population of cells guided by various oncogenic
events and pathways. In order to improve the success of targeted therapies, patients must
be categorized into responsive populations. Preliminary data has suggested advanced
stage patients exhibit activation of EGFR and NFκB signaling pathways. High gene copy
number of EGFR is frequent in HNSCCs and may be a sign of overly aggressive tumors.
A better understanding of the EGFR and NFκB pathways could improve the use of
targeted and combination therapies. The proposed studies are designed to provide
preclinical data in support of bortezomib or gefitinib as targeted agents in head and neck
squamous cell carcinomas. Effective combination therapies for patients with high EGFR
gene copy number require continued exploration.

CHAPTER 3: METHODOLOGY

Background
The frequent overexpression of EGFR in HNSCC and the demonstration of its
prognostic value have led to the evaluation of specific anti-EGFR agents as adjuncts to
conventional therapeutic regimens. The EGFR signaling pathway and its downstream
effectors play a key role in the growth of HNSCC and therefore represent attractive
targets for therapy. As these agents are introduced in clinical practice, the identification
of predictive markers for efficacy and toxicity becomes a crucial issue. The ultimate aim
is to be able to deliver a treatment tailored to each individual patient based on their
specific tumor profile. The objective of this study was to determine the potential
chemosensitivity of HNSCCs with EGFR amplification to combination treatments using
bortezomib, a proteasome inhibitor and gefitinib, an intracellular tyrosine kinase EGFR
inhibitor. See Table 2 for a summary of experimental procedures.
Specific Aims
The primary goal of this study was to investigate the effects of the combined
inhibition of bortezomib with gefitinib on human head and neck carcinoma cell lines with
EGFR amplification. Specific aims of this study can be summarized as follows:
1) To test the hypothesis that bortezomib could enhance the cytotoxic effects of
gefitinib in HNSCC cell lines, MTS assays were performed as a measure of cellular
47
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Table 2. Summary of Experimental Procedures.
Aim
Determine the effects
of bortezomib and
gefitinib Aim
in cell lines
with normal and
increased EGFR gene
copy number.

Determine the
differences in the
activation of EGFR
downstream proteins
between normal and
increased EGFR gene
copy number after
gefitinib dosing.
Determine the
differences in the
signaling pattern of
NFκB in cell lines
with normal and
increased EGFR gene
copy number.

Hypothesis
Increased synergistic
effects will result from
Hypothesis of
the administration
bortezomib with
gefitinib in cell lines
with increased EGFR
gene copy number.

Methods
PCR and Western blot to
determine EGFR gene
Method
amplification
and increased
protein expression in cell
lines.

Mechanisms of
bortezomib response
will be determined by
the expression of target
proteins in the
canonical NFκB
pathway.

DNA binding assay
measuring NFκB/RelA
nuclear activation levels to
determine target presence for
bortezomib.

Cell proliferation measured
by MTS assay to establish
baseline responses to single
drug dosing and effects of
bortezomib and gefitinib in
combination.
Mechanisms of
Western blots of downstream
gefitinib response will
EGFR pathways markers:
be determined by
EGFR, Akt, STAT3, &
expression levels of
MAPK to determine protein
downstream effectors of expression levels before and
the EGFR pathway.
after gefitinib treatment.

proliferation after agent treatment with each drug alone then again after the use of
bortezomib and gefitinib in combination. Three head and neck cell lines with EGFR gene
amplification (SQ20B, HN5, HSC-3) as confirmed by real-time quantitative polymerase
chain reaction (qPCR) were chosen for comparison to three EGFR wild-type (SCC25,
SCC1, 1CC8) head and neck cell lines. 1CC8 is a cetuximab resistant clone developed
from the SCC1 cell line and was used to assess anti-EGFR inhibitor resistance as an
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additional factor in drug sensitivity. Single agent IC50 levels, a measure of drug
concentration required for 50% inhibition of cellular growth, for both gefitinib and
bortezomib were established for each cell line. 1CC8, an EGFR wild-type cell line
proved equally resistant to lower doses of gefitinib and responsive to bortezomib on
equivalent levels to EGFR amplified cell lines, eliminating EGFR resistance as an
additional factor for study. To maintain equal comparisons between EGFR amplified
groups and wild-type cell lines, four of the original six cell lines were chosen (the two
most bortezomib responsive EGFR amplified cell lines, SQ20B and HN5 and the two
most gefitinib responsive EGFR wild type cell lines, SCC25 and SCC1) for further drug
combination studies by MTS assay using gefitinib, bortezomib and a specific NFκB
inhibitor, bay 11-7082. Bay 11-7082 served to further isolate the importance of
specificially inhibiting the NFκB pathway in these four cell lines.
2) To test the hypothesis that gefitinib response in head and neck cell lines is
associated with a tumor’s dependence on the EGFR pathway, western blot assays
were performed to measure changes in protein expression levels of the three major
downstream pathways of EGFR. To stimulate the EGFR pathway in the four cell lines
(SQ20B, HN5, SCC25 and SCC1), TGFα, a primary ligand for EGFR was applied to
serum starved cells for 30 minutes. Serum starvation involves the application of cell
culture media minus fetal bovine serum (FBS) for 24 hours in order to isolate the effects
of TGFα and activation of the EGFR pathway without interference from other growth
factors normally present in FBS that could stimulate additional pathways (Mather &
Roberts, 1998). Three cell culture plates were established for each cell line: baseline
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protein levels without TGFα or drug stimulation, TGFα stimulation only, and 0.1μM
gefitinib for 24 hours followed by TGFα stimulation for 30 minutes to measure the drug’s
ability to inhibit downstream pathways upon ligand stimulation. This dose of gefitinib
was chosen based on previous studies by Sebastian et al indicating doses as low as
0.064μM were recorded in cell lines responsive to gefitinib (Sebastian, et al., 2008).
Protein was then extracted for each cell line, run on a gel and probed for the three major
EGFR downstream pathway markers: phosporylated Akt, total Akt, phosphorylated
STAT3, total STAT, phoshorylated MAPK, and total MAPK by western blot analysis.
3) To test the hypothesis that bortezomib response in head and neck cell lines is
dependent on the presence of NFκB activity through the canonical pathway, DNA
binding assays were used to measure the nuclear protein expression levels of RelA in
SQ20B, HN5, SCC25, SCC1, Hep2, and HSC-3 after TNFα stimulation. SQ20B, Hep2
and SCC25 were shown to be most responsive to bortezomib by MTS assay. HN5 was
intermediate in response to bortezomib while SCC1 and HSC-3 were the two most
resistant cell lines as measured by MTS assay. In preparation for DNA binding assays,
three culture plates were established for each cell line and serum starved for 24 hours to
isolate the effects of the ligand TNFα, the primary ligand for the canonical pathway of
NFκB. The three culture plates consisted of: baseline nuclear protein levels without
TNFα or drug stimulation, TNFα stimulation only, and 0.1μM bortezomib for 24 hours
followed by TNFα stimulation for 30 minutes to measure the drug’s ability to inhibit
RelA upon ligand stimulation. The concentration of 0.1μM bortezomib for 24 hours was
chosen based on previous studies by Allen et al. showing bortezomib was able to
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suppress TNFα-induced RelA in head and neck cell lines using the same concentration
over 24 hours (Allen et al., 2009).
Because DNA binding results indicated off-target effects (targets of cytotoxicity
other than NFκB) for bortezomib in SQ20B and SCC25, Ingenuity Pathway Analysis
(IPA) was employed comparing the gene sets of the two most bortezomib sensitive cell
lines SQ20B and Hep2 versus the two most resistant cell lines tested, HSC-3 and SCC1.
IPA determines which pathways are significantly linked to the microarray gene set
previously compiled by the Chung laboratory and compared to the whole Ingenuity
knowledge base. The analysis revealed p53 as the top significant pathway to be
associated with the gene set. Western blot analysis was used to assess the p53 protein
expression level differences in SQ20B, HN5, SCC25, SCC1, Hep2 and HSC-3 cell lines
before and after bortezomib treatment.
Specific Aim 1
Cell Culture
Six cell lines were chosen from the Chung laboratory inventory for establishing
gefitinib and bortezomib sensitivity by MTS assay. These six cell lines were taken from
the original inventory of thirty-two HNSCC cell lines and were chosen based on the
perimeters of likely EGFR gene amplification (SQ20B, HN5 & HSC-3) in addition to a
negative status for human papilloma virus as previously determined by PCR in the Chung
laboratory. Matching EGFR wild-type cells (SCC25 and SCC1) were chosen for
comparison to SQ20B, HN5 & HSC-3. 1CC8 was the only cell line with intrinsic antiEGFR inhibitor resistance. EGFR gene amplification was verified by real- time PCR.
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HaCat cells were established for use as control cells for quantitative comparison in realtime qPCR assays. HaCaT cells are human keratinocyte cells with normal EGFR
expression commonly used as control cells (Chung, Parker, Levy, Slebos, Dicker, &
Rodeck, 2007; Patel, Ramesh, Traicoff, Baibakov, Emmert-Buck, Gutkind, et al., 2005).
SQ20B was contributed by Ralph Weichselbaum at University of Chicago. SCC25 was
purchased through American Type Culture Collection (Manassas, VA). SQ20B and
SCC25 were maintained in 10% Fetal Bovine Serum (FBS), 1% Penicillin/Streptomycin,
0.4µg/mL hydrocortisone in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12
(Invitrogen, Carlsbad, CA). SCC1 was contributed by Thomas Carey, University of
Michican. 1CC8 is a cetuximab-resistant clone of SCC1 established in the laboratory of
Dr. Carey by continuous exposure to increasing concentrations of cetuximab over 6
months (Wheeler et al., 2008). 1CC8 and SCC1 were maintained in 10% FBS, 1%
Penicillin/Streptomycin, 0.4µg/mL hydrocortisone in Dulbecco’s Modified Eagle’s
Medium (Cellgro, Manassas, VA). HSC-3 was provided by the Japanese Collection of
Research Bioresources (Shinjuku, Japan). HSC-3 was maintained in 10% FBS, 1%
Penicillin/Streptomycin in Minimum Essential Medium (Invitrogen). HN5 was
contributed by Ludwig Institute for Cancer Research (New York, NY). HN5 was
maintained in 10% FBS, 1% Penicillin/Streptomycin, and 0.8µg/mL hydrocortisone in
Dulbecco’s Modified Eagle’s Medium with 4.5 g/L Glucose, L-glutamine, & sodium
pyruvate (Cellgro, Manassas, VA). HaCaT cells were purchased from Cell Lines Service
(Eppelheim, Germany). HaCaT cells were maintained in MCDB-153 media (Mediatech,
Manassas, VA) supplemented with 2% FBS and 1% penicillin/streptomycin.
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Cell Line Verification
The integrity of each cell line, SQ20B, HN5, HSC-3, SCC1, 1CC8, HaCaT and
Hep2 (described in Specific Aim 3) was verified by STR (single-locus short tandem
repeats) typing using the AmpFLSTR Identifiler PCR Amplification Kit from Applied
Biosystems (Carlsbad, CA). STR are located at specific loci in the genome of each cell
line. The DNA typing process of cell lines involves simultaneously amplifying 15 STR
loci by polymerase chain reaction. Due to the highly polymorphic nature of each STR
loci, every cell line will have a unique molecular pattern that can distinguish it from other
sources. Analysis was conducted by the Fragment Analysis Facility at John Hopkins
University (Baltimore, Maryland) in March 2010. Each cell line, SQ20B, HN5, HSC-3,
SCC1, 1CC8, HaCaT and Hep2 proved unique in typing results.
Real-Time Polymerase Chain Reaction
To determine the specific amplification status of EGFR in SQ20B, HN5, HSC-3,
1CC8, SCC1, SCC25, and HaCaT cell lines, real time PCR was performed using the
DNA MasterMix SYBR Green (BioRad, Hercules, CA) and a iCycler IQ (Bio-Rad,
Hercules, CA). DNA was isolated from seven HNSCC cell lines using Ambion
RecoverAll Total Nucleic Acid Isolation kit (Ambion Inc., Austin, TX) according to the
manufacturer’s protocol. Cell line DNA was tested for the expression of EGFR using a
specific primer for exon 18 (forward: 5'-AGCATGGTGAGGGCTGAGGTGAC-3';
reverse: 5' ATATACAGCTTGCAAGGACTCTGG-3') producing a 262 base pair
amplifying product. Exons 18–21 of the EGFR gene are standard for analysis of
mutations, as this is where EGFR mutations are clustered (Sharma, Bell, & Settleman,
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2007). Primers for GAPDH (forward: 5'-GTTCGACAGTCAGCCGCATC-3'; reverse: 5'GGAATTTGCCATGGGTGGA -3') were used as a positive internal control for
amplification. PCR was performed as follows: an initial incubation step at 95°C, 40
amplification cycles of 95°C for 10 seconds, 60°C for 45 seconds, and a final extension
cycle of 72°. Relative changes in EGFR gene expression were determined by the 2 -ΔΔCT
method (Livak & Schmittgen, 2001) normalized to GAPDH and relative to normal
human keratinocyte cell line, HaCaT. Results were completed in triplicate and averaged.
Normalized EGFR gene expression values are presented as means ± standard deviation
(SD).
MTS Assay
The [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium, inner salt] (MTS) assay is a colorimetric method for
determining the number of viable cells in proliferation or cytotoxicity assays. Growth
inhibition was measured using the CellTiter 96 Aqueous One Solution Assay (Promega,
Madison, WI) as recommended by the manufacturer. The CellTiter 96 Aqueous One
Solution contains MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium, inner salt] compound and an electron coupling reagent PES
[phenazine ethosulfate]. The MTS compound is bioreduced by mitochondrial enzymes of
cells into a colored formazan product that is soluble in tissue culture medium. The
quantity of formazan product as measured by the amount of 490nm absorbance is directly
proportional to the number of living cells in culture. After 2 hours of incubation under
standard conditions of 5% CO2 and 37°C, the purple formazan product (indicative of
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reduction of MTS) was visible. Three head and neck cell lines verified for EGFR gene
amplification (SQ20B, HN5, HSC-3) were compared to three EGFR wild-type cell lines
(SCC25, SCC1 and 1CC8) and used for drug sensitivity assays.
Bortezomib (Millennium Pharmaceuticals, Cambridge, MA) was purchased from
the Vanderbilt Pharmacy. Bortezomib was diluted in 0.9% sodium chloride at 1mM
concentrations before being further diluted in culture medium prior to each experiment.
Gefitinib was purchased from Tocris Bioscience (Ellisville, Missouri). Gefitinib was
diluted in dimethyl sulfoxide (DMSO) at 1mM before being further diluted in culture
medium prior to each experiment. Cells were seeded in flat-bottom 96-well culture plates
with 2x103 cells per well in quadruplicate at each dose level on day 0. The drugs were
added on day 1: bortezomib or gefitinib at 0.01μM, 0.1μM, and 1μM, and kept in the
media for 48 or 72 hours.
The absorbance was read at 48 and 72 hours using the BioTek Synergy HT
microplate automated reader (Biotek Instruments, Winooski, VT) at 490 nm. The signal
generated (color intensity) is directly proportional to the number of viable (metabolically
active) cells in the wells. Relative cell numbers can therefore be determined based on the
optical absorbance (optical density, OD) of the sample. The blank values (media only)
were subtracted from each well of the treated cells and controls (saline only, the carrier
solution for bortezomib or DMSO only, the carrier solution for gefitinib); and the mean
and standard error for each treatment (single dose experiments and combination drug
experiments) were calculated relative to the control. Background readings from untreated,
control cells using the CellTiter 96 AQueous Systems are typically 0.1-0.3 absorbance

56
units. Culture media without cells (blank values) for each cell type was used in each
experiment to provide a background absorbance value which was subtracted from all
wells. Each data point represents the mean of four wells from three separate experiments.
Data Analysis
Single Agent Drug Studies
Statistical analysis was performed using unpaired Student’s t test (two-tailed
distribution) using SPSS version 15 comparing untreated control cells with treated cells
when measurable IC50 levels were achieved at either the 48 or 72 hour time points for
single agent drug studies.
In each cell culture plate, the first row (row A) contained medium only without
cells, providing a base value of absorption when conducting the MTS Assay. Since each
cell line experiment was done in triplicate, the results from each row were averaged to
find the mean absorption for a certain concentration. The mean background absorbance
value was subtracted from each row of averaged drug concentration value to achieve the
normalized value. Table 3A represents the average of three separate experiments. For
example, in the SCC25 cell line data above, the normalized value for gefitinib 0.01μM is
calculated by subtracting the average medium only value (0.152) from the average
concentration value for 0.01μM (1.2032) to reach the final normalized value 1.0509. The
control value column is then calculated by taking the normalized value and dividing it by
the control value, i.e. 1.0509/1.1589= 0.9068, to find the control rate for each drug
concentration. These values are then plotted onto the graphs seen in Chapter IV: Results.
These graphs show the decreasing viability of cells with increasing drug concentrations.
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Table 3A. Example Data Analysis for Determining Single Agent Gefitinib Response in
SCC25 Cells.
SCC25
Gefitinib
Medium (Row A)
Control (DMSO)
Gefitinib 0.01μM
Gefitinib 0.1μM
Gefitinib 1μM

1st
0.139
1.387
1.162
1.026
0.448

2nd
0.152
1.183
1.361
1.011
0.466

3rd
0.166
1.327
1.161
1.092
0.587

4th
Ave Normalized
.151 0.152
1.348 1.3112
1.1589
1.129 1.2032
1.0509
0.915 1.011
0.8586
0.593 0.5235
0.3711

Control
Rate
1
0.9068
0.7409
0.3202

The 100% viability mark is found at the point where no drug is being used to treat the
cells (control value of 1). The point where 50% cell viability is achieved is where the
IC50, will be noted except in cases of drug resistance. In the case of the SCC25 data the
IC50 value was found between the concentrations of 0.1 μM and 1 μM doses of gefitinib
calculated as shown in Table 3B.
Table 3B. Example Data Analysis for Determining Gefitinib IC50 Level in SCC25 Cells.
Gefitinib 72 hours
IC50

SCC25

A:concentration of more than 50%
B:concentration of less than 50%
C:inhibition rate of B
D:inhibition rate of A
IC50

.1
1
68
26
.373

Using the control rates found in Table 3A, the inhibition rate at 0.1μM concentration is
26% and the inhibition rate at 1μM concentration is 68% resulting in an IC50 of 0.373 for
SCC25 at 48 hours of gefitinib exposure. Data was calculated using Microsoft Excel.
Drug Combination Studies
Bay 11-7082 was diluted in dimethyl sulfoxide (DMSO) at 1mM before being
further diluted in culture medium prior to each experiment (Sigma, St. Louis, MO).
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Single agent IC50 levels were determined for bay 11-7082 over 48 hours in triplicate
before combination studies were continued. For the evaluation of antiproliferative effects
of bortezomib in combination with gefitinib or bay 11-7082, three schedules were
performed: (1) bortezomib for 24 hours followed by gefitinib for 24 hours or gefitinib for
24 hours followed by bortezomib for 24 hours, (2) bortezomib or bay 11-7082 for 24
hours followed by gefitinib for 24 hours, gefitinib for 24 hours followed by bortezomib
or bay 11-7082, (3) simultaneous incubation of gefitinib with bortezomib or bay 11-7082
over 48 hours. HNSCC cell viability was then determined by MTS assay (Promega,
Madison, WI). Dosage levels were determined for each inhibitor based on IC50 levels
established in single agent experiments. Gefitinib did not reach an IC50 level in SQ20B,
HN5, SCC25, and SCC1 at 48 hours, therefore for combination experiments gefitinib was
dosed at 0.5μM concentrations, half the maximal dosage used in single agent studies to
determine if synergistic combinations would be possible with these drugs in combination.
Experiments were performed in triplicate.
The ANOVA or Kruskal-Wallis statistical tests were performed for drug
combination studies involving bortezomib/gefitinib and gefitinib/bay 11-7082. The
independent variable was the effect of combining gefitinib and bortezomib (or bay 117082) in combination or sequentially. The dependent variable was the percent cell
viability resulting from these drug combinations. Cell viability results were normalized to
the mean of the control and analyzed using the Student’s t-test for single agents and
ANOVA or Kruskal-Wallis for drug combination analysis. The statistical analysis was
performed with SPSS for Windows, version 15.0 (SPSS, Inc., Chicago, IL). The
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significance of differences among multiple groups was assessed using ANOVA. When
the data sets failed the normality test, the Kruskal-Wallis one-way ANOVA was used.
The distribution of cell viability data was assessed using boxplots generated by SPSS.
Levene’s and Welch’s test for equality of variance was computed and analyzed
for violations of normality. Non-significant results indicated assumption of homogeneity
was met. When the assumption of homeogeneity was not met as indicated by significant
Levene’s and Welch’s tests, the Kruskal-Wallis nonparametric test was employed. This
test is comparative to ANOVA and is used when the assumption of normality is violated
(Gravetter & Wallnau, 2006). In the ANOVA, an F ratio was calculated which represents
the variance between the drug combination groups divided by the variance within the
groups. A large F ratio indicates more variability between groups (caused by the
independent variable) than within groups. A significant (P <0.05) F test rejects the null
hypothesis that the population means are equal.
Specific Aim 2
Cell Culture
SQ20B, HN5, SCC1 and SCC25 were established as previously described (p. 54)
and used to demonstrate the response of head and neck cell lines to gefitinib after
stimulation of the EGFR pathway using the ligand TGFα (10ng/μl) after serum
starvation. Serum starvation for 24 hours allowed for isolation of the effects of the EGFR
pathway through TGFα ligand stimulation. Differences in downstream pathway response
between EGFR amplified cell lines SQ20B and HN5 versus SCC25 and SCC1 was
measured by protein expression levels before and after gefitinib drug dosage (0.1μM)
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after 24 hours. This dose of gefitinib was chosen based on previous studies by Sebastian
et al indicating doses as low as 0.064μM were sufficient for cell inhibition in HNSCC
cell lines (Sebastian, et al., 2008).
Western Blotting
Cellular protein extracts were analyzed for EGFR downstream pathway
expression differences via Western blotting analysis. SQ20B, HN5, SCC1 and SCC25
were lysed with RIPA lysis buffer (1mM NaVO3,1mM DTT, 1mM PMSF, phosphatase
inhibitor cocktail and protease inhibitor cocktail mini tablet; Roche, Indianapolis, IN),
then sonicated. Protein concentration was quantified with a standard Bradford absorbance
assay using a microplate luminometer. Thirty micrograms of whole cell lysate from
SQ20B, HN5, SCC25 and SCC1 was mixed with Laemmli loading buffer (containing βmercaptoethanol) and heated at 95°C for 10 min. Samples were loaded onto 7.5% Trisglycine precast gels and electrophoresed for 1.5 hours at 115V on a Biorad MiniPROTEAN Tetra cell (Bio-rad, Hercules, CA). Proteins were transferred to a
polyvinylidene fluoride (PVDF) membrane at 30V overnight at 4°C using a Biorad Tetra
Blotting Module and incubated with rabbit anti-EGFR antibody and its activated form
phosphoryated EGFR Tyr1068. To measure the activated status of EGFR, an antibody
targeting the tyrosine phosphorylation site Tyr1068 was chosen for analysis as studies
indicate it mediates signaling to Akt and MAPK pathways (Pernas, et al., 2009). The
three major downstream pathways were assessed using antibodies targeting
phosphorylated p44/42 MAPK, total MAPK, phosphorylated Akt, total Akt, and
phosphorylated STAT3, total STAT3, (Cell Signaling Technology, Boston, MA) at the
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dilution of 1:1000, followed by secondary antibody at 1:3000 dilution for anti-rabbit or
1:5000 dilution for anti-mouse. Anti-rabbit β-actin or anti-GAPDH antibody was used as
a loading control (Cell Signaling Technology, Boston, MA). All antibodies were diluted
in Odyssey Blocking Buffer (Li-cor Bioscience, Lincoln, NE, USA). Each blot was
incubated with Amersham ECL plus Western Blotting Detection Reagents for the
detection of EGFR, and its downstream proteins, β-actin or GAPDH and exposed to
HyBlot CL Autoradiography Film (Denville Scientific, Metuchem, NJ). Experimental
band intensity for each sample was determined relative to the corresponding loading
control band using National Institutes of Health Image J, a public domain Java image
analysis and processing program http://rsbweb.nih.gov/ij/. Image J allows for comparing
the intensity of bands on a Western blot to standard proteins (β-actin or GAPDH) which
are converted into pixels that represent quantitative values. This allows for relative
intensity comparisons. The absolute intensity of each sample band (SQ20B, HN5, SCC25
or SCC1 for instance) is divided by the absolute intensity of the standard to come up with
a unitless value for the relative intensity of each sample band. Some bands will have a
relative intensity lower than 1 (they have less protein than the standard), and some bands
might have a relative intensity larger than 1 (they have more protein than the standard).
Specific Aim 3
Cell Culture
Head and neck cell lines were established for subsequent analysis by DNA
binding assay for measurement of NFκB nuclear binding activity after bortezomib
dosing. SQ20B, HN5, HSC-3, SCC1, and SCC25 were analyzed for bortezomib
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sensitivity by MTS assay as previously described (p. 54-56). Hep2, obtained from
Nobuhiko Oridate from Hokkaido University, was added as an additional bortezomib
sensitive cell line and maintained in DMEM with 5% FBS and 1%
Penicillin/Streptomycin. All cell lines were serum starved for 24 hours. Serum starvation
for 24 hours allowed for isolation of single pathway response to TNFα and the resulting
canonical pathway of NFκB stimulation. Differences in nuclear expression levels of
NFκB/RelA between the six cell lines was measured by DNA binding assays before and
after 0.1μM bortezomib drug dosage for 24 hours.
MTS Assay
Hep2, an EGFR wild-type cell line, was previously established as a bortezomibsensitive cell line in the laboratory and was reassessed for bortezomib sensitivity by MTS
assay over 48 and 72 hours using previously established methods (p.54). HSC-3 was
previously verified as bortezomib resistant by MTS Assay and added as an additional
resistant cell line for analysis; see Results, Figure 13 (p. 75).
Nuclear Extraction and DNA Binding Assays
Having established by MTS Assay that SQ20B, Hep2 and SCC25 were
significantly sensitive to bortezomib, the DNA binding assay was employed to determine
the nuclear localization and activation of NFκB/RelA before and after TNFα stimulation.
Nuclear cell extracts were prepared from serum starved cell lines SQ20B, HN5, SCC25,
SCC1, Hep2 and HSC-3 by employing a kit from Active Motif (Carlsbad, CA). At the
end of the incubations with bortezomib at 0.1μM for 24 hours with or without TNFα
stimulation for 30 minutes, the cells were washed, collected in ice-cold PBS in
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The presence of phosphatase inhibitors and centrifuged at 500 rpm for 5 min. This time
and concentration of bortezomib (0.1μM) was chosen based on studies by Allen et al.,
demonstrating TNFα-induced RelA sensitivity to bortezomib in head and neck cell lines
(Allen et al., 2009). The pellets were then resuspended in a hypotonic buffer, treated with
detergent and centrifuged at 14,000 g for 30 sec. After collection of cytoplasmic fraction,
the nuclei were lysed and nuclear proteins solubilized in the lysis buffer in the presence
of protease inhibitor cocktail. The concentration of the nuclear extract was determined
using a standard Bradford Assay using a microplate luminometer.
The binding of NFκB to DNA was measured in nuclear extracts with a specific
TransAM NFκB p65 assay kit from Active Motif, according to manufacturers’
instructions. This assay is based on the use of multi-well plates coated with an
oligonucleotide containing the consensus binding site for NFκB. Nuclear proteins (5ug)
were added to each well and incubated for 1 h to allow the binding of NFκB to this
oligonucleotide. The presence of the DNA-bound transcription factor was then detected
by the primary antibody that recognizes an epitope on p65 only when NFκB is activated
and bound to its target DNA. After addition of an anti-rabbit secondary antibody the
results were quantified by spectrophotometry. The absorbance was determined on a
spectrophotometer (Microplate reader model 550, Bio-Rad) at 450 nm with a reference
wavelength of 655 nm. The absorbance is proportional to the amount of NFκB p65 RelA
bound to DNA. NFκB-binding activity of testing samples, controls, and blanks were
measured in duplicate and averaged for statistical analysis. The statistical analysis of the
data was performed by using ANOVA. P values <0.05 were considered significant.
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Ingenuity Pathway Analysis
The Ingenuity Pathway knowledge base is the world's largest database of
biological networks created from millions of individually modelled relationships between
proteins, genes, complexes, cells, tissues, drugs, and diseases. Ingenuity Pathway
Analysis (IPA) is a web-based software application that enables the researcher to identify
pathways most relevant to their experimental datasets of interest. Relationships are
modeled among genes identified in RNA screens performed by the researcher
(http://www.ingenuity.com/). A microarray is a tool for analyzing gene expression that
consists of a small membrane, chip or glass slide containing samples of many genes
arranged in a regular pattern. The DNA is printed, spotted, or actually synthesized
directly onto the support. A researcher uses the location of each spot in the array to
identify a particular gene sequence. The spots themselves can be cDNA or
oligonucleotides. mRNA is isolated from each cell type and used as templates to generate
cDNA with a "fluorescent tag" attached. Different tags (red and green) are used so that
the samples can be differentiated in subsequent steps. The two labeled samples are then
mixed and incubated with a microarray containing the immobilized genes. The labeled
molecules bind to the sites on the array corresponding to the genes expressed in each cell.
The microarray is then placed in a scanner that consists of lasers, a special microscope,
and a camera. The fluorescent tags are excited by the laser, and the microscope and
camera work together to create a digital image of the array. These data are then stored in
a computer, and a special program is used to calculate the red-to-green fluorescence ratio
for each microarray spot by analyzing the digital image of the array. The program
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thencreates a table that contains the ratios of the intensity of red-to-green fluorescence for
every spot on the array. By isolating mRNA from the head and neck cell lines, SQ20B,
Hep2, HSC-3 and SCC1, comparisons were able to be made in terms of gene expression
through this microarray technique (Burguete, S., & McLachlan, G., 2009). Using the
microarray data generated for SQ20B, Hep2, HSC-3 and SCC1, gene expression results
were imported into the Ingenuity Pathway Analysis database, comparing bortezomib
resistance and sensitivity profiles between SQ20B and Hep2 to SCC1 and HSC-3.
Statistical analysis was done using Linear Model for Microarray Data (LIMMA).
LIMMA is a well-known bioinformatics package for differential expression analysis of
data arising from microarray experiments. The LIMMA package analyzes data from
comparisons between two or more groups of samples simultaneously. The analysis is
accomplished by fitting a linear model to the expression data for each gene. The main
advantage of LIMMA over the regular t-test is that LIMMA uses Empirical Bayes and
other shrinkage methods to borrow information across genes, whereas the t-test treats
each gene as an independent observation. Thus LIMMA is more representative of the real
gene regulation within the biological model (Smyth, 2004). The gene expression profile
of bortezomib sensitive cell lines SQ20B and Hep2 was compared to bortezomibresistant cell lines HSC-3 and SCC1. Examination of these genes on the context of
biologic pathways using IPA revealed p53 as a key signaling pathway.
Western Blot Analysis
To explore the off-target effects of bortezomib in SCC25 and SQ20B, Western
blot analysis was performed to assess p53 protein stabilization after drug treatment
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in SQ20B, HN5, SCC25, HN5, HSC-3 and Hep2. Using previously described methods
for western blot analysis (p.60), protein was extracted from serum starved cell lines
SQ20B, HN5, SCC25, SCC1, Hep2 and HSC-3 before and after 24 hour bortezomib
treatment at a concentration of 0.1μM. Protein extracts were quantified using a standard
Bradford Assay and subjected to Western blotting assay using an anti-p53 antibody at
1:1000 dilution followed by anti-rabbit secondary at 1:3000 (Santa Cruz Biotechnology,
Santa Cruz, CA). Bands were quantified using Image J analysis as previously described
(p.61).

CHAPTER IV: RESULTS

Specific Aim 1
In this study, HNSCC cell lines SQ20B, HN5, HSC-3, 1CC8, SCC25, and SCC1
which express differing amounts of the EGFR gene were used to assess the efficacy of
bortezomib and gefitinib. The cell lines were analyzed by qPCR in triplicate using
primers spanning the exon 18 sequence of the receptor. An upregulated level of EGFR
gene expression was noted in SQ20B (6 fold), HN5 (4 fold) and HSC-3 (3 fold)
compared to the baseline receptor expression in SCC25, SCC1 and 1CC8 (Figure 4).
Relative EGFR copy number
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Figure 4. EGFR Amplification Status in HNSCC Cell Lines.
EGFR DNA expression was presented as the fold change in EGFR gene expression
normalized to GAPDH and relative to human keratinocyte cell line, HaCaT. Results are
reported in triplicate with error bars representing standard deviation.
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Single Agent Drug Studies
Three EGFR amplified cell lines, SQ20B, HN5 and HSC-3, as assessed by PCR
were chosen to assess drug sensitivity to gefitinib in order to establish baseline levels for
subsequent combination studies. Three wild-type cell lines with normal EGFR receptor
levels, SCC25, SCC1 and 1CC8, as assessed by PCR were chosen for drug sensitivity
assessment in comparison. 1CC8 was derived from the parental SCC1 cell line by
chronic, repeated exposure to cetuximab. Although 1CC8 is an EGFR wild-type line, the
EGFR inhibitor resistance phenotype allowed for assessment of targeted agent treatment
resistance using a drug with a similar mode of action. This provided an additional factor
for analysis in drug sensitivity. Cetuximab is an antibody that binds to the extracellular
domain of EGFR, preventing its activation and tumor-promoting effects.
In response to gefitinib treatment, all three EGFR amplified cell lines, SQ20B,
HN5 and HSC-3 demonstrated resistance to doses of 1μM and less over 48 and 72 hour
time points of exposure. Each cell line (2 x103 cells/well) was cultured in 96-well plates
for 24 hr to allow 70-80% confluence then treated with varying concentrations (0.01μM,
0.1μM & 1μM) of gefitinib for 48 & 72 hours. Data points represent means of three
independent experiments performed in triplicate with error bars representing standard
error of the mean. The percent survival is plotted relative to control cells. Cells were
assessed for post-treatment viability using the MTS assay. IC50 levels were not reached at
either 48 hour or 72 hour time points for either SQ20B or HN5 (Figures 5 and 6).
Although cell proliferation was downregulated slighlty by gefitinib at the 0.01μM
concentration in HSC-3 cells, recovery of growth occurred at the 0.1μM drug dosage and
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Figure 5. Gefitinib Treatment in EGFR Amplified Cell Line SQ20B.
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Figure 6. Gefitinib Treatment in EGFR Amplified Cell Line HN5.
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remained resistant up to the 1μM dose (Figure 7). Compensatory signaling mechanisms
Gefitinib HSC-3 cells
Treated for 48 & 72 hours
1.05

1

HSC-3
48 hours

0.9

HSC-3
72 hours

% cell viability

0.95

0.85

0.8
control

Gef 0.01μM

Gef 0.1μM

Gef 1μM

Drug Concentration

Figure 7. Gefitinib Treatment in EGFR Amplified Cell Line HSC-3.
may contribute to this cell lines’ ability to recover survival pathways through activation
of alternative receptors. pAkt is known to be upregulated in EGFR amplified cells lines,
necessitating higher concentrations of gefitinib to suppress resistant cell populations.
Sergina et al demonstrated that increased expression of additional ErbB receptors in
addition to upregulated Akt contributes to escape mechanisms in cancer cell signaling
(Sergina, Rausch, Wang, Blair, Hann, Hann, et al., 2007).
1CC8 also demonstrated resistance to gefitinib at doses of 1μM and less at both
time points (Figure 8). SCC1 showed a trend towards sensitivity at the 48 hour time point
but did not reach an IC50 level until the 72 hour time point with a significant
concentration of 0.274μM by Student’s t test (P=0.031) (Figure 9).
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Figure 8. Gefitinib Treatment in EGFR Wild-Type Cell Line 1CC8.
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Figure 9. Gefitinib Treatment in EGFR Wild-Type Cell Line SCC1.
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SCC25 showed significant sensitivity to gefitinib (P=0.023) with an IC50 of
0.475μM at the 48 hour time point and 0.373μM at the 72 hour time point with the use of
the Student’s t test (Figure 10). Graphical representation of MTS results for gefitinib in
each cell line are shown below followed by summarized results (Table 4).
Gefitinib SCC25 cells
Treated for 48 & 72 hours
1.4

1.2

% cell viability

1

SCC25
48 hours

0.8

SCC25
72 hours

0.6

0.4

0.2

0
control

Gef 0.01μM

Gef 0.1μM

Gef 1μM

Drug Concentration

Figure 10. Gefitinib Treatment in EGFR Wild-Type Cell Line SCC25.
Table 4. Summary of Single Dose Gefitinib Results in HNSCC Cell Lines.
Cell Line
SQ20B
HN5
HSC-3
1CC8
SCC1
SCC25

EGFR status
Amplified
Amplified
Amplified
Wild-type
Wild-type
Wild-type

Gefitinib IC50
48 hours
72 hours
IC50>1μM
IC50>1μM
IC50>1μM
IC50>1μM
IC50>1μM
IC50>1μM
IC50>1μM
IC50>1μM
IC50>1μM
0.274μM (P=0.031)*
0.475μM (P=0.023)* 0.373μM (P=0.069)

Note: * indicates significance using Student’s t test at P<0.05.
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In this study, SQ20B, HN5, HSC-3, 1CC8, SCC25 and SCC1 were evaluated for
sensitivity to bortezomib as a single agent using the MTS cell proliferation assay to
establish baseline levels for subsequent combination studies. Three cell lines with EGFR
amplification as determined by PCR analysis, SQ20B, HN5 and HSC-3 were chosen to
assess drug sensitivity. Three wild-type cells lines with normal EGFR receptor levels as
determined by PCR analysis, SCC25, SCC1 and 1CC8, were chosen for drug sensitivity
assessment in comparison. 1CC8 is a cetuximab resistant clone derived from the SCC1
cell line with normal EGFR receptor levels. The addition of 1CC8 allowed for the
assessment of EGFR inhibitor resistance as an additional factor in targeted agent
sensitivity. 1CC8 proved resistant to single agent gefitinib as expected but this particular
resistance phenotype has not been assessed in squamous cell carcinomas of the head and
neck. Each cell line was analyzed for single agent bortezomib sensitivity using MTS
assays. Each assay was performed in triplicate and shown in graphical format with error
bars representing standard error of the mean.
In response to bortezomib treatment, cell line SQ20B showed greatest sensitivity
to the drug, with an IC50 value of 0.328μM at 48 hours and 0.038 μM at 72 hours which
proved significantly different from control cells by Student’s t test (P=0.008) (Figure 11).
HN5 also demonstrated sensitivity to bortezomib at the 48 hour and 72 hour time points
with 0.473μM and 0.407μM doses, respectively (Figure 12). Although not as sensitive as
SQ20B, HN5 showed an intermediate level of response to bortezomib. This cell line’s
response to bortezomib did not prove significantly different from control cells by
Student’s t test.
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Figure 11. Bortezomib Treatment in EGFR Amplified Cell Line SQ20B.
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Figure 12. Bortezomib Treatment in EGFR Amplified Cell Line HN5.
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HSC-3 proved resistant without a measurable IC50 at either the 48 or 72 hour time
points (Figure 13). The resistance profile of HSC-3 at both 48 and 72 hours remains to be
explored. Additional analyses were necessary to further define a bortezomib responsive
profile in both EGFR amplified and wild-type cell lines. In general, the EGFR amplified
cell lines SQ20B and HN5 demonstrated sensitivity to bortezomib after three days of
exposure to the drug. 1CC8 showed sensitivity to bortezomib with an IC50 of 0.338μM
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Figure 13. Bortezomib Treatment in EGFR Wild-Type Cell Line HSC-3
at the 72 hour time point, although this did not prove significant by Student’s t test
(Figure 14). SCC25 was significantly inhibited by bortezomib at 0.422μM over 72 hours
(Figure 15). SCC1 required higher levels of the drug to elicit a response after 72 hours of
exposure compared to its EGFR resistant clone 1CC8. Both cell lines were resistant to
bortezomib at 48 hours of exposure. SCC1 had an IC50 level of 0.728μM at the 72 hour
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Figure 14. Bortezomib Treatment in EGFR Wild-Type Cell Line 1CC8.
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Figure 15. Bortezomib Treatment in EGFR Wild-Type Cell Line SCC25.
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time point (Figure 16). Graphical representation of MTS results for bortezomib in each
cell line are shown below followed by summarized results (Table 5).
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Figure 16. Bortezomib Treatment in EGFR Wild-Type Cell Line SCC1.
Table 5. Summary of Single Dose Bortezomib Results in EGFR Amplified and
Unamplified Cell Lines.
Cell Line

EGFR status

Bortezomib IC50
48 hours

72 hours

SQ20B

Amplified

0.328μM (P=0.104)

0.038 μM (P=0.008)*

HN5

Amplified

0.473 μM (P=0.299)

0.407 μM (P=0.08)

HSC-3

Amplified

IC50>1μM

IC50>1μM

1CC8

Wild-type

IC50>1μM

0.338 μM (P=0.947)

SCC1

Wild-type

IC50>1μM

0.728 μM (P=0.563)

SCC25

Wild-type

IC50>1μM

0.422 μM (P=0.031)*

Note: * indicates significance using Student’s t test at P<0.05.
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Drug Combination Studies
Single agent sensitivity profiles were previously established for gefitinib and
bortezomib in SQ20B, HN5, SCC25 and SCC1 using drug dosages up to 1μM (see
Figures 5-16). To assess sensitivity to gefitinib and bortezomib in resistant cell lines,
MTS assays were performed using higher doses of bortezomib and gefitinib until IC 50
levels were reached in each cell line that previously demonstrated resistance to lower
doses of inhibitors (i.e. when IC50 levels were not reached at doses of 1μM or less at 48
hours). Higher dose single agent results are demonstrated in combination graphs. Bay 117082 was added as an additional inhibitor to assess the specific inhibition of the NFκB
pathway. 1CC8 was eliminated for further study based on consistent results with EGFR
amplified cell lines, indicating EGFR inhibitor resistance was not a defining factor in
targeted agent resistance.
The most bortezomib sensitive EGFR amplified cell lines, SQ20B and HN5 were
chosen for further combination studies. SCC25 and SCC1 were chosen as comparison
EGFR wild-type cell lines due to their gefitinib responsive profiles (see Figure 6).
SQ20B, HN5, SCC25 and SCC1 were treated with bortezomib, gefitinib or bay 11-7082
alone or in combination for 48 hours. Bay 11-7082 as a monotherapy in each cell line
was established for baseline levels for combination studies. SCC25 proved most
responsive to bay 11-7082 over 48 hours at an IC50 of 3.9 µM, although this was not
significant. SQ20B had an IC50 level of 32µM, HN5 an IC50 level of 26µM and SCC1 an
IC50 level of 24µM, none of which proved significantly different from control cells as
assessed by Student’s t test.
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Cells were seeded at 2x10 in 96-well plates, grown overnight, then treated for 48
3

hours with the indicated concentrations of bortezomib, gefitinib or bay alone or in
combination. Data were plotted as the percent of cell viability relative to untreated
control wells and displayed in graphical form. Error bars represent standard deviation in
all combination experiments.
Table 6. IC50 levels of Gefitinib and Bortezomib as Single Agents in HNSCC Cell Lines.
Cell Line
SQ20B
HN5
SCC25
SCC1

48 hours (μM)

72 hours (μM)

Bortezomib
0.328
0.038
0.473
0.407
>1
0.422
>1
0.728

48 hours (μM)

72 hours (μM)

Gefitinib
>1
>1
0.475
>1

>1
>1
0.373
0.274

Note: Previously established drug sensitivity levels as seen in Figures 5-16.
EGFR overexpressing cell lines SQ20B and HN5 were sensitive to bortezomib
alone after 48 hours as demonstrated previously. Only SQ20B proved significantly
inhibited by single agent bortezomib. In the EGFR overexpressing cell lines, the
combination of both bortezomib and gefitinib and pre-exposure with bortezomib
demonstrated increased sensitivity compared to pre-exposure with gefitinib, although no
combination demonstrated significantly increased sensitivity over bortezomib as a single
agent. Bortezomib did demonstrate a sensitizing effect for gefitinib by decreasing cell
viability at smaller drug concentrations for SQ20B (Figure 17). The addition of bay 117082 also provided a sensitizing effect for gefitinib in SQ20B (Figure 18). As in SQ20B,
bortezomib demonstrated a sensitizing effect for gefitinib by decreasing cell viability at
smaller drug concentrations for HN5. The benefit of bortezomib pre-exposure in the cell
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Figure 17. SQ20B Combination Experiments with Bortezomib (Bort) and Gefitinib (Gef).
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Figure 18. SQ20B Combination Experiments with Bay 11-7082 (Bay) and Gefitinib
(Gef)
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line HN5 did not appear to be as notable as that in SQ20B (Figure 19). Bay 11-7082 was
1.6
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Figure 19. HN5 Combination Experiments with Bortezomib (Bort) and Gefitinib (Gef).
not able to demonstrate a sensitizing effect for gefitinib in the HN5 cell line. The addition
of bay 11-7082 did not provide any additional cytotoxic effects in HN5 as a monotherapy
or in combination with gefitinib (Figure 20). EGFR wild-type cell lines SCC25 and SCC1
demonstrated similar responsive profiles as SQ20B and HN5 when bortezomib was
applied before gefitinib. SCC25 and SCC1 were sensitive to gefitinib alone but were
insensitive to bortezomib after 48 hours of drug exposure as shown previously. Higher
doses of bortezomib were required to achieve cellular proliferation using single agent
bortezomib for SCC25 over 48 hours. Cellular proliferation increased at the 0.01μM and
0.1μM dosages until inhibition was achieved at the 1μM-10μM dosage range using
bortezomib as a monotherapy (Figure 21).

82

HN5
1.4
1.2

% Cell Viability

1
0.8
0.6

HN5 Bay
HN5 Gef
HN5 Bay+Gef
HN5 Bay→Gef (0.5μM)
HN5 Gef (0.5μM)→Bay

0.4
0.2
0
-0.2

control

0.01μM

0.1μM
1μM
Drug Concentration

10μM

100μM

Figure 20. HN5 Combination Experiments with Bay 11-7082 (Bay) and Gefitinib (Gef).
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Figure 21. SCC25 Combination Experiments with Bortezomib (Bort) and Gefitinib (Gef).
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Similar results were noted using the MTS Assay to analyze single agent bortezomib
response in SCC25 over 48 hours. Longer exposure times were required (72
hours) to achieve IC50 levels in this cell line (see Figure 16). Bortezomib’s ability to
suppress cell proliferation through off-target effects may require increased drug
concentrations as well as longer exposure times. Previous studies suggest NFκB may not
be the only determinant of bortezomib activity in HNSCCs (Allen et al, 2008, Kisselev &
Goldberg, 2001, Williams & McConkey, 2003). Bortezomib also downregulates or
disrupts other resistance pathways or mechanisms, such as the p44/42 MAPK pathway
(Schwartz & Davidson, 2004). The addition of bay to gefitinib did not prove superior in
SCC25 over single agent treatment with gefitinib (Figure 22).
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Figure 22. SCC25 Combination Experiments with Bay 11-7082 (Bay) and Gefitinib
(Gef).
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The combination of both inhibitors and pre-exposure with bortezomib
demonstrated increased cytotoxicity compared to pre-exposure with gefitinib. Gefitinib as
a monotherapy in SCC25 cells was comparable to combination treatments with
bortezomib and gefitinib. Similar results were noted in SCC1 with combination
treatments using bortezomib and gefitinib with the combination being equally effective as
gefitinib alone (Figure 23). The addition of bay to gefitinib did not prove superior in
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Figure 23. SCC1 Combination Experiments with Bortezomib (Bort) and Gefitinib (Gef).
SCC1 over single agent treatment with gefitinib (Figure 24). The significance of
differences among drug combinations was assessed using ANOVA. When the data sets
failed the normality test, the Kruskal-Willis one-way ANOVA was used. The null
hypothesis was accepted if P < 0.05. The ANOVA and Kruskal-Willis tests revealed
nonsignificant effects for the combinations of bortezomib and gefitinib or gefitinib and
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bay 11-7082 in SQ20B, HN5, SCC25 or SCC1. Statistical results of drug combination
regimens between the four cell lines are displayed below (Table 7).
SCC1 Bay
SCC1 Gef
SCC1 Bay+Gef (0.5μM)
SCC1 Gef (0.5μM)→Bay
SCC1 Bay→Gef (0.5μM)
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Figure 24. SCC1 Combination Experiments with Bay 11-7082 (Bay) and Gefitinib (Gef).
†

Table 7. ANOVA and Kruskal-Wallis Results for Drug Combination Studies.
Cell Line

Drug combo

Df

F

P

SQ20B

Bort + Gef

14

1.215

0.331

Bay + Gef

14

2.853

0.097

Bort + Gef

3

Χ=6.651†

0.084

Bay + Gef

14

0.165

0.850

Bort + Gef

14

1.682

0.227

Bay + Gef

14

0.212

0.812

Bort + Gef

3

Χ=3.380 †

0.185

Bay + Gef

14

0.076

0.928

HN5

SCC25

SCC1
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Summary
In the EGFR overexpressing cell lines, the combination of both inhibitors and the
pre-exposure of bortezomib followed by gefinitib demonstrated increased sensitivity
compared to gefitinib pre-exposure followed by bortezomib, although no combination
demonstrated significantly increased sensitivity over bortezomib monotherapy.
Bortezomib did demonstrate a sensitizing effect for gefitinib by decreasing cell viability
at smaller drug concentrations for gefitinib. The sequential addition of bay 11-7082
followed by gefitinib demonstrated a trend towards sensitivity over other bay
combinations in SQ20B although none of the bay 11-7082 inhibitor concentrations
proved significantly superior in the four cell lines.
EGFR wild-type cell lines were sensitive to gefitinib alone but were insensitive to
bortezomib after 48 hours of drug exposure. The combination of both inhibitors and preexposure of bortezomib before gefitinib demonstrated a trend towards increased
sensitivity compared to gefitinib pre-exposure before bortezomib. Gefitinib as a
monotherapy in SCC25 and SCC1 cells was comparable to combination treatments with
bortezomib and gefitinib. The addition of bay 11-7082 to gefitinib did not prove superior
in either EGFR wild-type cell line over gefitinib monotherapy.
Specific Aim 2
Western Blotting
The second specific aim of this study was to characterize gefitinib sensitivity in
HNSCC’s that is predictive of treatment response. It was hypothesized that the
mechanisms of gefitinib response would be determined by expression of Akt, MAPK and

87
STAT3 of the EGFR pathway. It was hypothesized that increased activity of EGFR and
its downstream pathways in EGFR amplified cell lines SQ20B and HN5 was responsible
for gefitinib resistance. To examine this possibility, a primary ligand for the EGFR
receptor TGFα was used to stimulate the EGFR pathway while examining the activation
levels of the three major downstream pathways: STAT3, Akt and MAPK. Gefitinib was
applied at a dose of 0.1μM for 24 hours to serum starved cells followed by post-treatment
with TGFα stimulation. Serum starvation allowed for isolation of TGFα-stimulated
effects without interference from additional activating factors present in serum. To
measure activation of EGFR, an antibody targeting the tyrosine phosphorylation site
Tyr1068 was chosen for analysis as studies indicate it mediates signaling to Akt and
MAPK pathways (Pernas, et al., 2009). Gefitinib effectively downregulated
phosphorylated (p) EGFR in all cell lines. Although EGFR was activated in the wild-type
cell line SCC25, gefitinib suppressed activation of the receptor more effectively in
comparison to the EGFR amplified cell lines SQ20B and HN5. Total EGFR levels were
highly expressed in SQ20B and HN5 at baseline levels and after TGFα stimulation.
Gefitinib did not suppress the activity of total EGFR protein expression (Figure 25A).

Figure 25A. Western Blot Assay of pEGFR Tyr 1068 in HNSCC Cell Lines.
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Activated Akt was elevated at baseline levels for both EGFR amplified cell lines,
SQ20B and HN5. Less dependence of this pathway was noted for the EGFR wild-type
cell lines, SCC25 and SCC1. Gefitinib was able to suppress phosphorylated Akt activity
in all four cell lines. Minimal differences were noted in total Akt levels between the four
cell lines (Figure 25B).

Figure 25B. Western Blot Assay of phosphorylated Akt in HNSCC Cell Lines.
SCC25 demonstrated the highest TGFα-stimulated expression of phosphorylated
MAPK and interestingly an increase in this downstream marker after gefitinib dosing.
The remaining cell lines demonstrated variable baseline levels of phosphorylated MAPK
and increases in ligand-stimulated expression but were downregulated by gefitinib. Total
MAPK levels were unaffected by gefitinib treatment (Figure 26A).

Figure 26A. Western Blot Assay of phosphorylated MAPK (p44/42).
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Phosphorylated STAT3 was highly expressed in HN5 and SCC25 as a result of
TGFα stimulation. Gefitinib effectively reduced phosphorylated STAT3 expression in the
two cell lines, demonstrating increased ligand-stimulated expression, HN5 and SCC25.
SCC1 demonstrated high levels of baseline phosphorylated STAT3 levels that remained
unchanged after TGFα stimulation and increased after gefitinib administration indicating
potential compensation of this cell line through other pathways unaffected by gefitinib.
SQ20B did express basal protein expression levels of phosphorylated STAT3 protein,
which remained unchanged by ligand stimulation or gefitinib inhibition (Figure 26B).
STAT3 expression may be occurring through alternate pathways in this cell line.

Figure 26B. Western Blot Assay of phosphorylated STAT3 in HNSCC Cell Lines.
Summary
While gefitinib does appear to be effective in downregulating activation of EGFR
and its three main pathways, the degree of inhibition can vary between cell lines. The
activated form of the receptor is completely inhibited in the cell lines SCC25 and SCC1,
the two most responsive cell lines to lower doses of gefitinib. Although gefitinib is also
able to downregulate the activation of EGFR in SQ20B and HN5, this effect is less
inhibitory. Phosphorylated Akt is also effectively suppressed in all four cell lines by
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gefitinib, although baseline levels and ligand-stimulated protein levels remain highest in
the two more resistant cell lines SQ20B and HN5. Gefitinib was able to inhibit activated
MAPK in all cell lines except SCC25 which increased after drug dosing. SCC1
responded similarly to phosphorylated STAT3 with increasing protein expression after
gefitinib dosing.
Specific Aim 3
MTS Assay
The third specific aim of this study was to characterize bortezomib sensitivity and
its dependence on the NFκB pathway. Head and neck cell lines SQ20B, HN5, SCC25,
SCC1, and HSC-3 were previously established for bortezomib sensitivity by MTS Assay
as demonstrated in Figures 11-16. Variable results to bortezomib were noted between
EGFR amplified and wild-type cell lines. SQ20B and SCC25 proved to be significantly
responsive to bortezomib while the remaining cell lines demonstrated variable but
unsignificant sensitivity to the targeted agent. Hep-2, an EGFR wild-type cell line, was
added as an additional cell line for analysis by DNA binding assay for measurement of
NFκB nuclear binding activity after bortezomib dosing. Hep-2 cells (2 x103 cells/well)
were cultured in 96-well plates for 24 hr to allow 70-80% confluence then treated with
varying concentrations (0.01μM, 0.1μM & 1μM) of bortezomib for 48 and 72 hours. The
percent survival is plotted relative to control cells. Data points represent means of three
independent experiments performed in triplicate. The bars indicate standard error of the
mean (SEM). Hep-2 proved significantly sensitive to bortezomib by Student’s t test with
an IC50 of 0.096 μM at 72 hours (P=0.011) (Figure 27).
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Figure 27. Bortezomib Treatment in Hep-2 Cell Line.
Nuclear Extraction and DNA Binding Assay
To test the hypothesis that bortezomib response in head and neck cell lines is
dependent on the presence of NFκB activity through the canonical pathway, DNA
binding assays were used to measure the nuclear protein expression levels of RelA in
SQ20B, HN5, SCC25, SCC1, HSC-3, and Hep-2 after TNFα stimulation. TNFα is the
primary ligand for the canonical pathway of NFκB activity. After stimulation of the
canonical pathway, nuclear protein was isolated from each cell line and NFκB/RelA
levels measured using the DNA binding assay before and after bortezomib dosing.
SQ20B, Hep2 and SCC25 were shown to be significantly responsive to bortezomib by
MTS assay and were expected to demonstrate increased signaling through the canonical
pathway. HN5 was intermediate in response to bortezomib while SCC1 and HSC-3 were
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the two most resistant cell lines as measured by MTS assay. In preparation for DNA
binding assays three culture plates were established for each cell line and serum starved
for 24 hours to isolate the effects of the ligand TNFα. The three culture plates consisted
of: baseline nuclear protein levels without TNFα or drug stimulation, TNFα stimulation
only, and 0.1μM bortezomib for 24 hours followed by TNFα stimulation for 30 minutes
to measure the drug’s ability to inhibit RelA upon ligand stimulation. The concentration
of 0.1μM bortezomib for 24 hours was chosen based on previous studies by Allen et al.
showing bortezomib was able to suppress TNFα-induced RelA in head and neck cell lines
using the same concentration over 24 hours (Allen et al., 2009).
Nuclear binding activity was measured in cell lines after 24 hours of 0.1μM
bortezomib treatment. SQ20B, Hep2, HSC-3 and SCC1 show significant inhibition of
TNFα inducible DNA binding of RelA. HN5 and SCC25 demonstrated minimal increases
of TNFα inducible DNA binding of RelA likely representing non-dependence on the
NFκB pathway. * (P<0.05) denotes significant difference in NFκB DNA binding.
Bortezomib was able to significantly decrease NFκB/RelA nuclear activity in SQ20B,
Hep-2, HSC-3 and SCC1 by ANOVA (Figure 28). HN5 demonstrated increased binding
activity whereas SCC25 demonstrated no change in NFκB/RelA binding after bortezomib
dosing. Hep-2 and HSC-3 demonstrated the highest increases in NFκB/RelA binding in
response to TNFα ligand stimulation as compared to the remaining cell lines. Hep-2
responded to bortezomib with a greater decrease in RelA binding as compared to resistant
cell line HSC-3. The remaining bortezomib-sensitive cell lines, SQ20B and SCC25
demonstrated much lower levels of RelA binding in response to TNFα stimulation.
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Figure 28. DNA Binding Activity of RelA in HNSCC Cell Lines.
Ingenuity Pathway Analysis
DNA binding results showed likely off-target effects (targets of cytotoxicity other
than NFκB through the effects of non-specific proteasome inhibition) for bortezomibsensitive cell lines SQ20B and SCC25 as a result of lower levels of response to TNFα
stimulation. IPA was employed comparing the gene sets of the two most bortezomib
sensitive cell lines SQ20B and Hep2 versus the two most resistant cell lines tested, HSC3 and SCC1. This analysis determined which pathways were significantly linked to the
microarray gene set previously compiled by the Chung laboratory (see Materials and
Methods p. 70-71) and compared to the whole Ingenuity knowledge base. The analysis
revealed p53 as the top significant pathway associated with the gene set. p53 is encoded
by the TP53 gene (shown in red) determined to be significantly upregulated in
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bortezomib-sensitive cells as compared to bortezomib-resistant shown below (Figure 29).

Figure 29. p53 Pathway Network Generated from Ingenuity Pathway Analysis.
Ingenuity Pathway Analysis was employed to identify biological networks that
were affected by bortezomib sensitivity versus resistance between SQ20B and Hep 2
(two sensitive cell lines) versus HSC-3 and SCC1 (two resistant cell lines). Nodes
represent genes/gene products identified by the network. Color intensity indicates
significance of upregulated genes from most significant (dark red) to least significant
(light pink). Green represents a decrease in gene expression. Shapes represent the
functional class of the gene product: concentric circles equal a complex, down-pointing
triangles equal kinases, diamonds equal enzymes, horizontal ovals equal transcription
regulators, vertical ovals equal transmembrane receptors, vertical rectangles equal Gprotein coupled receptors, horizontal rectangles equal ligand-dependent nuclear receptors
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and circles represent other entities. Solid lines indicate direct interactions between nodes
whereas dashed lines represent indirect interactions. Lines beginning and ending at a
single node show self-regulation, while a line without an arrowhead represents binding.
Western Blot Analysis
Based on IPA analysis (see Figure 29), western blot analysis was employed to
assess the p53 protein expression level differences in SQ20B, HN5, SCC25, SCC1, Hep2
and HSC-3 cell lines before and after bortezomib treatment (Figure 30). SQ20B
demonstrated a small decrease in protein expression after 0.1μM bortezomib treatment
after 24 hours. HN5 demonstrated an increase in p53 levels after 24 hours of treatment.
Hep-2 cells demonstrated a low level of basal p53 protein level that decreased after
bortezomib treatment. The remaining cell lines, SCC25, SCC1 and HSC-3 were negative
for p53 protein at basal levels and after bortezomib treatment.
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Summary
The use of bortezomib as a monotherapy in solid tumors other than
hematological carcinomas has so far yielded disappointing results. Bortezomib gained
widespread attention for its ability to suppress NFκB which is constitutively active in
many tumors as a result of radiation and cytotoxic therapies including head and neck
cancer (McConkey & Zhu, 2008). Effective sequence administration of bortezomib may
be important to its use in a responsive population. Because bortezomib’s effects are
targeted later in the cell cycle, the use of other agents may arrest the cell cycle before the
point at which bortezomib is maximally effective. The data presented here in
combination studies suggest similar kinetics with the use of gefitinib before bortezomib.
In an attempt to further characterize bortezomib response, RelA activity was measured in
four HNSCC cell lines by DNA binding assay. Activation levels varied between
responsive and resistant cell lines, suggesting bortezomib’s effectiveness is not limited to
suppression of the NFκB pathway. Cancer cells have the ability to utilize a number of
signaling pathways in order to avoid apoptosis and maintain cell survival. A detailed
understanding of the complex signaling networks necessitates the optimal design of
targeted therapies in head and neck cancers.

CHAPTER V: DISCUSSION

Specific Aim 1
Patient response to targeted agents such as gefitinib is suggested to depend mainly
on the level of expression of the target in the tumor. So far, EGFR protein expression
alone has not been a reliable marker for gefitinib response. A high copy number for the
EGFR gene, on the other hand, may be a more effective molecular predictor of outcome.
Clarification of the molecular mechanisms responsible for gefitinib's effects is needed to
maximize the clinical benefits of targeted therapy with anti-tyrosine kinase inhibitors of
EGFR. Bortezomib is one of the newest agents for targeted therapy, developed to
specifically inhibit the proteasome, leading to increased apoptosis. Borteomib is currently
being explored for clinical use in solid tumors. By targeting the proteasome, bortezomib
affects numerous regulatory proteins necessary for malignant cells to proliferate, leading
to apoptosis. The focus of this study was to analyze the relationship between EGFR gene
amplification in HNSCC cell lines and their response to gefitinib and bortezomib as
monotherapies and in combination. Combinations of these and other targeted agents may
overcome the resistance that develops with single-agent therapy and could be
incorporated either as part of initial therapy or later when disease resistance develops.
Distinct differences were demonstrated within the context of EGFR expression status as
indicated by measurable IC50 levels over 72 hours of exposure. EGFR amplified cell lines
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to gefitinib. However, findings indicate significant bortezomib sensitivity is present in
only two cell lines, SQ20B, an EGFR amplified cell line and SCC25, an EGFR wild-type
were generally more responsive to bortezomib with the exception of HSC-3, but
resistantcell line. DNA binding results indicate HSC-3 has increasingly high NFκB/RelA
activity through the canonical pathway that may overwhelm bortezomib’s ability to
effectively suppress cellular proliferation. EGFR wild-type cells SCC1 and SCC25
demonstrated increased sensitivity to lower doses of gefitinib but generalized resistance
to bortezomib with the exception of SCC25. Higher doses of gefitinib (>1μM) were
required to achieve cytotoxicity in all four cell lines over 48 hours.
Clinical data on the predictive value of EGFR for gefitinib response in HNSCC
are limited; however, in agreement with the in vitro data presented here, the gene
expression levels of EGFR were not predictive of gefitinib response for HNSCC tumors
at lower concentrations. This study noted higher concentrations of gefitinib were
necessary to achieve IC50 levels by MTS Assay in EGFR gene amplified and EGFR overexpressing cell lines SQ20B and HN5. Simply assessing the quantity of EGFR in cell
lines or tumors may not always give a reliable assessment of the EGFR-stimulated
signaling activity or dependence of the tumor on downstream signaling. Consistent with
the reports conducted by Pernas et al and Sebastian et al using EGFR–overexpressing
head and neck cell lines, increased EGFR expression may not be definitive for gefitinib
sensitivity (Sebastian et al., 2008; Pernas et al., 2009).
Previous studies suggest that heterodimerization of EGFR with other ErbBs is
associated with resistance to EGFR inhibitors. This was in line with findings suggesting
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higher concentrations of tyrosine kinase inhibitors like gefitinib are needed to
suppressEGFR phosphorylation in cancer cells that also express high levels of ErbB2
when compared with cells expressing EGFR alone (Arteaga 2002).
Cellular cytotoxicity by bortezomib is most likely the result of several
mechanisms of inhibition including the NFκB pathway. There remains controversy
regarding if and how much of the cytotoxic effect of bortezomib is dependent on NFκB
activation. Bortezomib was able to significantly block cell proliferation in SQ20B and
SCC25, an EGFR amplified and EGFR wild-type cell line respectively. Variable results
were noted in the remaining cell lines. Although IC 50 levels were achieved at 72 hours
with the remaining cell lines with the exception of HSC-3, these results did not prove
significant. The present data is consistent with findings from previous studies noting the
high prevalance of NFκB expression in head and neck tumors is an important but not the
only determinant of bortezomib activity in HNSCCs (Allen et al, 2008, Kesselev &
Goldberg, 2001, Williams & McConkey, 2003).
The rationale for combining bortezomib and gefitinib is based on their reported
targeting of pathways contributing to treatment resistance. In this study, it was
demonstrated that phenotypic differences in EGFR expression can account for certain
differential drug sensitivities between bortezomib and gefitinib in HNSCC cell lines but
was not definitive in determining drug response. Increased activation of the EGFR may
overwhelm gefitinib’s ability to inhibit downstream signaling, contributing to resistance
in EGFR amplified cell lines. Bortezomib sensitivity and resistance profiles remain less
delineated in the context of EGFR amplification. Although EGFR amplified cell lines
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demonstrated a trend towards bortezomib sensitivity, significant IC 50 levels were
alsomeasured in the unamplified cell lines SCC25 and Hep2 after 72 hours. Further
characterization of pathway dependence between each cell line is necessary while
considering bortezomib’s broad range of cytotoxic actions.
Since EGFR and NFκB inhibitors alone show limited effect in inhibiting growth
of EGFR-expressing tumors, it is hypothesized that a combinatorial approach of
bortezomib and gefitinib might be useful in augmenting growth suppression. This study
also sought to further characterize and define the relevance of the NFκB pathway in
HNSCCs through the use of a specific IKK inhibitor, bay 11-7082.
Overexpression of EGFR is associated with poor prognosis in HNSCC, and
specific targets to the tyrosine kinase domain and proteasome have shown limited
survival benefits in HNSCC patients as a monotherapy in solid tumors. However, very
little is known about the mechanism of resistance, and currently there is no reliable
biomarkers of gefitinib or bortezomib sensitivity in HNSCCs. The rationale for
combining gefitinb and borezomib is based on their potential ability to block multiple
downstream pathways that may contribute to treatment resistance. The present study
shows increased cytotoxic activity using bortezomib as a monotherapy as well as a
sensitizer for gefitinib in cell lines with EGFR amplification, although the present data
does not support the use of combined inhibitors.
This study demonstrates that the nature of the interaction between bortezomib and
gefitinib may be schedule-dependent. Three possible schedules were assessed: i.e.,
bortezomib (or bay 11-7082) plus gefitinib, bortezomib (or bay 11-7082) followed by
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gefitinib, and gefitinib followed by bortezomib (or bay 11-7082), and found that
increased cell cytotoxicity is possible in EGFR amplified cell lines with sequential dosing
using bortezomib before gefitinib. These findings are consistent with the results of
Wagenblast et al that noted synergistic effects using combination treatments with antiEGFR inhibitors and bortezomib. Although Wagenblast used cetuximab, an extracellular
EGFR inhibitor in combination with bortezomib, these findings support the rationale for
combining anti-EGFR agents with proteasome inhibitors in HNSCC cell lines
(Wagenblast, Hambeck, Baghi, & Knecht, 2008). Cascone et al suggested that synergism
occurs when bortezomib is used prior to gefitinib, and may relate to the specific
activation of the Akt pathway (Cascone et al, 2008). Piperdi et al also noted a cell cycle
dependence effect related to bortezomib pre-exposure in non-small cell lung cancer cells.
The use of the tyrosine kinase inhibitor erlotinib before the addition of bortezomib
resulted in G1 cell cycle arrest, antagonizing the activity of bortezomib. Bortezomib
works later in the cell cycle, causing G2/M cell cycle arrest. While pre-exposure with
erlotinib was found to be antagonistic, preventing bortezomib from exerting its effects
later in the cell cycle, dosing with bortezomib first or at the same time as erlotinib was
more effective (Piperdi, Ling, & Perez-Soler, 2007). A similar antagonistic effect was
apparent in all four cell lines studied here with gefitinib pre-exposure. EGFR wild-type
cell lines SCC25 and SCC1 demonstrated sensitivity to gefitinib monotherapy but were
less effectively inhibited by gefitinib pre-exposure which may be related to cell cycle
kinetics. McConkey et al studied similar effects in pancreatic cell lines with the
combination of bortezomib and the anti-mitotic chemotherapeutic agent docetaxel.
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Usingflow cytometry and immunoprecipitation, bortezomib was found to block the
apoptotic effects of docetaxel by acting earlier in the cell cycle (before M phase),
inhibiting the activation of cyclin dependent kinase (cdk). Docetaxel initiates apoptosis
by acting during the M phase causing apoptosis of rapidly dividing cells. Interestingly,
the administration of bortezomib after docetaxel offset the cell cycle effects but did not
increase the amount of cell death noted with the administration of docetaxel alone
(Nawrocki, Sweeney-Gotsch, Takamori, & McConkey, 2004). Kassouf et al noted that
the induction of G1 phase arrest before treatment renders human bladder carcinoma cells
less sensitive to docetaxel. Because gefitinib induces G1 phase arrest, an apoptotic effect
was enhanced only when gefitinib was administered after docetaxel (Kassouf, Luongo,
Brown, Adam, & Dinney, 2006). Cell cycle kinetics play a prominent role in sensitivity
to chemotherapeutic agents. It is expected that bortezomib, acting later in the cell cycle,
may not be as effective in cells pretreated with gefitinib, an early inhibitor of the cell
cycle. The use of gefitinib first may be abrogating the cytotoxic effects of
bortezomib as the cell cycle is arrested before bortezomib can exert its drug killing
effects.
The current study did not find the addition of an NFκB specific inhibitor, bay 117082, to be superior as a monotherapy or in combination with gefitinib in any of the cell
lines tested. Although SCC25 was the most sensitive of the cell lines to bay 11-7082 at
3.9μM, this dose did not prove significantly different from control values. SCC25 was
significantly inhibited by bortezomib after 72 hours which may indicate this cell line’s
dependence on other downstream markers or pathways as bortezomib is known to have
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multi-dimensional effects. Previous studies have demonstrated the inability of bay 117082 to affect Akt activation and therefore noncanonical pathways of NFκB activation
(Nakamura, Kawankami, Ida, Koji & Eguchi, 2007). Gasparian et al made a direct
comparison of various proteasome inhibitors to IKK inhibitors including bay 11-7082 in
prostate cancer cell lines and found NFκB to be more effectively suppressed through
proteasome treatment (Gasparain et al, 2009). While it is generally accepted that
bortezomib’s primary mode of action is suppression of the NFκB signaling pathway,
other important functions of proteasome inhibitors are implicated such as interruption of
the cell cycle machinery and increased apoptosis through endoplasmic reticulum (ER)
stress (McConkey & Zhu, 2008). The variable response of proteasome inhibitors in
certain solid tumors is linked to incomplete inhibition of both canonical and noncanonical
NFκB pathways (Allen et al., 2008).
Constitutive Akt activation can decrease bortezomib’s effectiveness and may even
be increased by bortezomib treatment (McConkey & Zhu, 2008). HN5 demonstrated a
the highest baseline pAkt expression levels of the four cell lines but only stabilized levels
of bortezomib inhibition over 48 and 72 hours. Akt may also be a central mediator in
gefitinib resistance as well. Gefitinib has been postulated to have decreased efficiency in
blocking downstream pathways of other tyrosine kinase receptors. Treatment with
gefitinib has been shown to increase the activity of other ErbB family members such as
ErbB2 and ErbB3. Akt is then upregulated through alternative receptor activation and
downstream signaling (Cooper & Cohen, 2009). NFκB inhibitors such as bay 11-7082
have shown a limited ability to suppress growth and block DNA binding of additional
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NFκB family members besides RelA (McConkey & Zhu, 2008; Allen et al., 2008).
Bortezomib has also been reported to primarily block RelA through the canonical NFκB
pathway but not IKKα-induced translocation of NFκB2/RelB through the noncanonical
pathway, contributing to drug resistance (Allen et al., 2008).
These experiments were intended to characterize differential drug sensitivities in
the context of EGFR expression status using MTS assays. EGFR gene and protein status
of cell lines were confirmed by qPCR and western blot respectively. The sequential
addition of bortezomib before gefitinib augmented the cytotoxic effects of gefitinib
monotherapy in EGFR amplified cell lines SQ20B and HN5, yet the combination did not
reveal significantly increased cytotoxicity over bortezomib alone. Gefitinib demonstrated
an antagonistic effect when administered before bortezomib in all four cell lines. These
results support single agent bortezomib as a viable treatment agent or as a sensitizer for
gefitinib in effectively suppressing cellular proliferation in HNSCC cell lines. Support for
combination treatment using gefitinib and bortezomib is cautious as the potential for
increased toxicities using dual agents may not justify the minimal effects from combining
these drugs. A specific NFκB inhibitor was not effective as a monotherapy or in
combination with EGFR inhibition, justifying further characterization of the NFκB
pathway in HNSCCs using additional experiments.
Specific Aim 2
The development of treatment resistance presents a significant obstacle toeffective tumor
control in advanced stage head and neck patients. Mechanisms of EGFR inhibitor
resistance were explored using western blots to monitor the activity of the three major
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downstream pathways of EGFR. As previously described, EGFR amplification
contributes to increased expression of the receptor on the cell surface. These results
suggest that elevated total EGFR expression and activity of the receptor in gefitinibresistant cells may be a contributor to decreased effectiveness of the drug. Drug
resistance of SQ20B and HN5 could not be simply explained by the level of TGFαinduced EGFR phosphorylation in that gefitinib effectively inhibited activation of the
receptor in all lines, although increased activation levels were noted in the EGFR
amplified cell lines SQ20B and HN5. SCC25, an EGFR wild-type cell line also displayed
increased activation of the receptor through the tyrosine phosphorylation site 1068 which
was completely downregulated by gefitinib. SCC1 demonstrated low to absent levels of
EGFR activation. SCC25 and SCC1 demonstrated decreased levels of basal pEGFR
activation and although SCC25 responded to ligand stimulation, activation of the receptor
was effectively inhibited in both cell lines. SQ20B and HN5 displayed a greater
dependence on the EGFR pathway and predominantly the downstream marker Akt.
Variable activation levels of the three major pathways was noted in the four cell
lines although it appears that pAkt may play a role in resistance as these results
demonstrate high levels of baseline expression in the EGFR amplified cell lines. These
findings suggest EGFR-dependent hyperphosphorylation of Akt may play an important
role in gefitinib response. In support of these results, Sergina et al demonstrated that the
activation of additional ErbB family members and Akt contribute to escape mechanisms
from the inhibiting effects of gefitinib in both in vitro and in vivo models (Sergina, et al.,
2007). MAPK and STAT3 activation appear to play less of a role in gefitinib resistance
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with these cell lines. EGFR amplified cell lines did demonstrate basal and TGFαstimulated expression of phosphorylated MAPK, although the expression levels were
downregulated by gefitinib. Activated STAT3 was primarily noted in the cell lines HN5
and SCC25 upon TGFα stimulation which was suppressed by gefitinib. SCC1
demonstrated elevated levels of activated STAT3 which did not increase upon TGFα
ligand stimulation or respond to gefitinib, suggesting alternative receptor activation of
this downstream protein in this cell line. SQ20B did express basal levels of pSTAT3 but
did not appear to signal through EGFR for this downstream protein as TGFα ligand
stimulation did not result in increased activation levels.
Pernas et al studied the effects of gefitinib on EGFR overexpressing and wild-type
HNSCC cell lines in vitro by MTT assay. Increased gefitinib doses were required to
achieve IC50 levels with ranges of response measuring from 1.1μM to 2.5μM over a five
day treatment period. Doses of 1μM were effective in suppressing levels of pAkt,
pSTAT3 and pMAPK. Also in agreement with the data presented here, total EGFR levels
were not affected by treatment. More responsive cell lines exhibited elevated basal levels
of pAkt whereas the resistant cell line, SCC-11B demonstrated the highest pSTAT3 basal
levels (Pernas et al., 2009). These results suggest a cell line dependence effect for
gefitinib. Lower doses of gefitinib (<1μM) may not be sufficient for complete
downregulation of amplified EGFR cell lines and resulting downstream pathways. The
concentration of 0.1 μM used in this study is significantly below the mean plasma steady
state concentration for gefitinib (0.4-1.4 μM) in patients (Mukohara, Engelman, Hanna,
Yeap, Kobayashi, Lindeman, et al., 2005). Amplification and/or overexpression of EGFR
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may contribute to disappointing responses noted with gefitinib in the clinical setting.
Response to tyrosine kinase inhibitors such as gefitinib in HNSCCs may be due to
deregulation of ErbB2 or ErbB3 rather than EGFR. Cooper et al showed treatment with
gefitinib in resistant breast cancer cells leads to increased expression of ErbB3 to the
plasma membrane. Treatment with gefitinib also increased ErbB3 trafficking to the
plasma membrane, where dimerization with ErbB2 and activation occurred. ErbB3 then
restores Akt signaling, since it is one of the primary activators of the PI3K/Akt pathway
(Cooper & Cohen, 2009). Gefitinib resistance appears to be associated with EGFR and
pAkt overexpression in this study, while sensitivity is associated with other factors. The
aim was to find unifying characteristics to better define gefitinib response in advanced
stage head and neck cancers, although these mechanisms of sensitivity appear to be
diverse between cell lines.
Although poorer patient prognosis is known to be associated with EGFR gene
amplification in HNSCC patients, what this means for optimal treatment regimens
remains to be determined. The underlying molecular mechanisms contributing to the
deregulation of EGFR require further investigation as targeted agents become
increasingly used in clinical settings. This data is supportive of EGFR amplification and
resulting pAkt overexpression as a contributing factor to gefitinib resistance, although
further studies with additional cell lines are required to eliminate individual cell line
variation. In addition, increased levels of basal pAkt may require higher dosages of
gefitinib to effectively induce cellular cytotoxicity. Elevated expression of MAPK and
STAT3 appear to be less relevant as markers of gefitinib sensitivity in these cell lines.
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Specific Aim 3
The NFκB signaling pathway plays an important role in the development of tumor
resistance to therapy and is known to be highly expressed in head and neck cancers. DNA
binding assays were used to evaluate the ability of bortezomib to block TNFα-induced
NFκB RelA activity. Bortezomib effectively interrupted TNFα-induced RelA activation
in four of the six cell lines tested, a result that has been demonstrated in other HNSCC
cell lines (Allen et al., 2008). The presence of EGFR amplification does not appear to
play a role in determining bortezomib response as variable results were noted in these cell
lines irrespective of receptor status. The three significantly sensitive cell lines included
the EGFR overexpressing SQ20B and wild-type cell lines Hep2 and SCC25. Dependence
on the NFκB pathway was also not conclusive for determining response to bortezomib as
SCC25 and SQ20B express relatively lower levels of RelA activity yet significant
response to the drug. Bortezomib may also downregulate other resistance pathways,
including the p44/42 MAPK pathway. Commonly activated by other chemotherapeutic
agents, proteasome inhibitors have been shown to block the activation of the p44/42
pathway leading to increased cell death (Schwartz & Davidson, 2004). This presents a
potential pathway of inhibition for SCC25 by bortezomib, as previous western blot data
demonstrated increased basal activation of MAPK in this cell line. The treatment of
HNSCC cells with bortezomib has been reported to led to upregulation of activated
STAT3, suggesting that the ability of bortezomib to kill HNSCC cells may be hindered
due to increased activity of cellular STAT3 protein (Marmor et al., 2004). The
bortezomib-resistant cell line SCC1 demonstrated increased basal levels of activated
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STAT3 by western blot that was unresponsive to 0.1μM gefitinib over 24 hours. Single
agent bortezomib may further elevate basal levels of this protein, preventing the drug
from effectively suppressing cell survival.
Studies have suggested a number of cellular toxicity effects through the
administration of bortezomib including stabilization of p53 and pro-apoptotic proteins,
increased apoptosis through the unfolded protein or endoplasmic reticulum stress
response and generation of oxygen species (McConkey & Zhu, 2008). Recent studies
have shown increased activity of the proteasome is correlated with resistance. Chronic
lymphocytic leukemia patients have increased proteasome activity and do not respond to
bortezomib (Orlowski & Kuhn, 2008). Allen et al produced findings that incomplete
inhibition of baseline RelA may contribute to the limited response to lower doses of
bortezomib as illustrated with HSC-3 by DNA binding results in this study. Additionally
IHC analysis of pre and post treatment biopsies by Allen et al revealed a lack of
inhibition on other members of the NFκB family by bortezomib (Allen et al., 2008).
Incomplete inhibition of RelB and c-Rel may contribute to survival and escape for
resistant cell lines SCC1 and moderately sensitive cell line HN5.
Conclusions
EGFR is highly expressed in most human head and neck cancer tumors. Despite
the prevalence of the receptor, EGFR-targeted agents as a monotherapy continue to
demonstrate disappointing results in clinical trials. Studies have not been able to correlate
EGFR protein expression status to anti-EGFR inhibitor sensitivity. Differences in
downstream pathways exist between head and neck tumors, although the defining
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phenotype that determines the optimal treatment regimen is not yet available. The current
study noted high levels of phosphorylated EGFR and the downstream protein Akt in
EGFR amplified cell lines, necessitating higher doses of gefitinib to achieve cytotoxicity.
Downstream signal molecules may hold the key as cell lines that use Akt signaling have
been shown to be gefitinib sensitive, although its overexpression, either by activation
through receptor crosstalk, activating mutations in PI3K or deactivating mutations in
PTEN may be an indicator of resistance. Combination therapies hold promise as the key
to overcoming treatment resistance. Although the combination of gefitinib and the
proteasome inhibitor, bortezomib did not prove superior in combination, cell cycle
dependent effects were noted. The present study shows superior cytotoxic activity using
bortezomib as a monotherapy as well as a sensitizer for EGFR amplified cell lines. The
administration of gefitinib after bortezomib produced anatogonist effects.
Gene expression analysis has suggested patients with advanced stage head and
neck cancer exhibit activation of NFκB signaling pathways. Bortezomib is a proteasome
inhibitor approved by the FDA for hematological malignancies that is currently being
investigated for effectiveness in solid tumors. As inhibition of NFκB is thought to be an
important target of bortezomib activity, its effects were compared with that of the more
specific NFκB inhibitor bay 11-7082, by inhibition of IKK. The cytotoxic effects of
bortezomib were found not to be completely dependant on its ability to downregulate
NFκB. Further characterization of these pathways is required to define those patients
most likely to respond to targeted therapies.
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Limitations
One potential limitation lies in the fact that only six head and neck cell lines
wereinitially examined for bortezomib and gefitinib response and these may not be
representative of all EGFR amplified and wild-type cell lines. Studies that examine the
association between EGFR amplification in HNSCC and the efficiency of bortezomib
with other EGFR inhibitors will help guide future targeted therapies to those patients
most likely to benefit. Additional assays were employed in this study to support drug
response results determined through MTS assays. Not all cell lines respond equally to
NFκB activating ligands like TNFα, either because they lack the required receptor or
because of missing downstream effectors (Pahl, 1999). Bortezomib has been reported to
cause cell cycle arrest at the G2-M phase in both sensitive and resistant cell lines.
Although cell cycle arrest is induced, apoptosis is not necessarily the resulting end-point.
MTS assays measure the number of proliferating cells but does not measure the level of
apoptosis after treatment (Chen, Yeh, Yeh, Lu, & Huang, 2008). Bortezomib sensitive
cell lines were determined by MTS assay in terms of cell proliferation, but DNA binding
served to conclusively measure the amount of activity and inhibition of NFκB. Western
blotting helped to further characterize cell line dependence on the EGFR pathway. DNA
binding assays reflected NFκB activity and helped further delineate bortezomib’s broad
cytotoxic actions. IPA identified pathways of relevance to bortezomib resistance and
sensitivity between the experimental set of head and neck cell lines.
Combination drug data was based on in vitro cytotoxicity profiles. The nature of
in vitro systems allow for results which may be cell line dependent and not necessarily
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based on phenotypic differences. These results did note a schedule-dependent result with
bortezomib pre-exposure producing increased cytotoxicity when compared to
simultaneous drug combinations or gefitinib pre-exposure in all four cell lines. These
results were comparable to other published studies conducted by Piperdi et al (Piperdi et
al., 2007). These authors, as in the current study, also examined a small number of cell
lines, four non-small cell lung cancer lines. To further establish the cell cycle effects of
bortezomib and tyrosine kinase inhibitors, a broader panel of cell lines requires
examination. Variable results are also noted when comparing drug sensitivities in vitro
versus in vivo. In this study, the combination of bortezomib and gefitinib in vitro was
unremarkable in comparison to single agent drug treatment. Nawrocki et al was unable to
demonstrate synergistic effects of bortezomib and docetaxel in vitro, although significant
effects were noted in vivo with combination treatment as the result of bortezomib’s
ability to suppress angiogenesis (Nawrocki et al., 2004). Similar effects may be possible
with the drug combination of bortezomib and gefitinib that would best be realized using
in vivo systems.
Ligand binding with EGFR results in receptor homo- or heterodimerization at the
cell surface, followed by internalization of the dimerized receptor. EGFR dimerization
stimulates its intracellular protein-tyrosine kinase activity. As a result,
autophosphorylation of several tyrosine (Tyr) residues in the C-terminal domain of EGFR
occurs. Tyr1086, Tyr992, Tyr1068, Tyr1148 and Tyr1173. Tyr 1068, Tyr 1148, and
Tyr1173, are the major sites of autophosphorylation, which occur as a result of EGF and
TGFα binding. After dimerization and internalization, autophosphorylation of the
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intracytoplasmic EGFR tyrosine kinase domains occur. Autophosphorylation induces
downstream activation and signaling by several other proteins that associate with these
phosphorylated tyrosines. The main EGFR signaling pathways, MAPK, Akt and STAT3
pathways are then initiated. It is theorized that different EGF-like growth factors may
affect receptor conformations which will determine specific tyrosine phosphorylation site
usage (Herbst 2004). This study evaluated the effects of pEGFR using an antibody
targeted to Tyr1068, a primary site of activation for the Akt and MAPK pathways.
Additional phosphorylated sites are capable of initiating Akt and MAPK pathways as
well and this data may not present the complete activated status of the three downstream
proteins. Pernas et al showed significant inhibition of three phosphorylated sites, Tyr845,
Tyr1068 and Tyr1173 in HNSCC cell lines after gefitinib dosing, indicating gefitinib is
effective at suppressing EGFR stimulated pathways at multiple sites of phosphorylation
(Pernas et al., 2009).
Recommendations for Further Studies
Mechanisms of resistance appear to be diverse between and within head and neck
cancer tissue types. Despite the development of new targeted anticancer therapies,
mechanisms continue to evolve to protect cells against cytotoxic compounds and act as
obstacles to successful treatment.
The choice of drug schedule administration may be important in terms of
inhibiting cell cycle progression. Although the combination of bortezomib and gefitinib
in vitro was less active than single agents in this study, the combined effect of these drugs
in vivo may demonstrate additional effects on angiogensis and warrants further study.
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Assays comparing the effects of bortezomib in pretreatment and post-treatment biopsies
on NFκB activity could be useful to develop biomarkers for clinical trials in advanced
stage head and neck cancers in which variable responses to bortezomib have been
observed. These biomarkers could be useful in classifying patients into potentially
responsive populations based on specific activation levels.
The selective inhibition of multiple signaling pathways in combination with
current chemotherapeutic drugs may lead to an increased potency and efficacy of these
agents. Additional studies are needed using gene array data to discern new potential
therapeutic targets for advanced stage head and neck cancer patients.
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